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ABSTRACT
POLYMERIC PEPTIDE MIMICS FOR PROTEIN DELIVERY
MAY 2018
CORALIE M. BACKLUND, B.S., OREGON STATE UNIVERSITY
M.A., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Gregory N. Tew

The plasma membrane is a major obstacle in the development and use of
biomacromolecules for intracellular applications. Consequently, proteins with intracellular
targets represent an enormous, yet under studied avenue for therapeutics. Extended
research has aimed at facilitating intracellular delivery of exogenous proteins using protein
transduction domains (PTDs), which allow transport of bioactive molecules into cells.
Synthetic polymers, inspired by PTDs, provide a well-controlled platform to vary
molecular architecture for structure activity relationship studies. Specifically, this thesis
focuses on the use of ring-opening metathesis, a facile and efficient polymerization
technique, through which we can vary structural parameters to optimize delivery of noncovalently encapsulated proteins. The aim was to characterize, optimize, and utilize PTD
mimics (PTDMs) for functional protein delivery. Fluorescently labeled cargo were used to
elucidate the predominant cellular entry mechanism for the PTDMs and were compared to
their ability to deliver protein into cells. A series of polymers was designed around the
most membrane active polymers to explore the incorporation of guanidine and hydrophobic
moieties, yielding a PTDM capable of high protein delivery into a variety of cell types. The
PTDM was then explored for use as a vaccine delivery reagent into immune cells. The
vi

ability to have a specific response with the cargo of interest verifies cytosolic delivery using
the PTDMs and provides valuable insight into their use to affect intracellular pathways.
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TABLE OF CONTENTS
Page
ACKNOWLEDGMENTS .............................................................................................. V
ABSTRACT ..................................................................................................................VI
LIST OF TABLES ........................................................................................................XI
LIST OF FIGURES ..................................................................................................... XII
GLOSSARY ............................................................................................................... XV
CHAPTER
1.

INTRACELLULAR DELIVERY OF FUNCTIONAL PROTEINS ......................... 1
1.1

Introduction ..................................................................................................... 1

1.2
Physical Delivery Methods............................................................................... 4
1.2.1
Microinjection .......................................................................................... 4
1.2.2
Electroporation ......................................................................................... 6
1.2.3
Microfluidics ............................................................................................ 7
1.2.4
Insight ...................................................................................................... 8
1.3
Lipid-Based Nanocarriers................................................................................. 9
1.3.1
Liposomes ................................................................................................ 9
1.3.2
Solid Lipid Nanoparticles ....................................................................... 10
1.3.3
Insight .................................................................................................... 11
1.4
Inorganic Nanocarriers ................................................................................... 12
1.4.1
Carbon Nanotubes .................................................................................. 12
1.4.2
Quantum Dots ........................................................................................ 13
1.4.3
Gold Nanoparticles ................................................................................. 15
1.4.4
Silica Nanoparticles................................................................................ 16
1.4.5
Magnetic Nanoparticles .......................................................................... 17
1.4.6
Insight .................................................................................................... 18
1.5
Protein and Peptide Mediated Carriers ........................................................... 18
1.5.1
Engineered Proteins................................................................................ 18
1.5.2
Exosomes ............................................................................................... 20
1.5.3
Virus Like Particles ................................................................................ 21
1.5.4
Protein Toxins ........................................................................................ 22
1.5.5
Cell Penetrating Peptides ........................................................................ 23
1.5.6
Insight .................................................................................................... 25
1.6
Synthetic Polymeric Nanocarriers .................................................................. 25
1.6.1
Protein Transduction Domain Mimics .................................................... 25
1.6.2
Nanogels ................................................................................................ 26
1.6.3
Polymeric Micelles ................................................................................. 28
1.6.4
Dendrimers............................................................................................. 29
1.6.5
Nanocapsules and Polymersomes ........................................................... 30

viii

1.6.6
1.6.7

Polyplexes .............................................................................................. 31
Insight .................................................................................................... 33

1.7

Perspective ..................................................................................................... 33

1.8

Thesis Overview ............................................................................................ 35

2. RELATING STRUCTURE AND INTERNALIZATION FOR ROMP-BASED
PROTEIN MIMICS ...................................................................................................... 38
2.1

Introduction ................................................................................................... 38

2.2
Materials and Methods ................................................................................... 42
2.2.1
Materials ................................................................................................ 42
2.2.2
Instrumentation ...................................................................................... 43
2.2.3
PTDM Synthesis .................................................................................... 43
2.2.3.1 Monomer Synthesis ............................................................................ 43
2.2.3.2 Activated Ester Synthesis ................................................................... 46
2.2.3.3 Polymer Synthesis .............................................................................. 47
2.2.4
Deprotection........................................................................................... 51
2.2.5
Internalization of FITC-Labeled Polymers .............................................. 51
2.2.6
EGFP Delivery ....................................................................................... 52
2.3
Results and Discussion ................................................................................... 53
2.3.1
Polymer Design and Synthesis................................................................ 53
2.3.2
Internalization of FITC-Labeled Polymers .............................................. 53
2.3.3
Co-localization with Lysosomes ............................................................. 56
2.3.4
Concentration Dependence ..................................................................... 57
2.3.5
EGFP Delivery ....................................................................................... 59
2.4

Conclusion ..................................................................................................... 61

3. INCREASED HYDROPHOBIC BLOCK LENGTH OF PTDMS PROMOTES
PROTEIN INTERNALIZATION .................................................................................. 63
3.1

Introduction ................................................................................................... 63

3.2
Materials and Methods ................................................................................... 66
3.2.1
PTDM Synthesis .................................................................................... 66
3.2.1.1 Monomers .......................................................................................... 66
3.2.1.2 Polymers ............................................................................................ 69
3.2.1.3 Deprotection ....................................................................................... 71
3.2.2
Characterization ..................................................................................... 72
3.2.2.1 Reverse Phase High Liquid Chromatography...................................... 72
3.2.2.2 Dynamic Light Scattering ................................................................... 72
3.2.3
Protein Delivery ..................................................................................... 72
3.2.3.1 Suspension Cells ................................................................................ 72
3.2.3.2 Adherent Cells .................................................................................... 73
3.2.3.3 Confocal Laser Scanning Microscopy ................................................. 74
3.3
Results and Discussion ................................................................................... 74
3.3.1
PTDM Design ........................................................................................ 74
3.3.2
Dynamic Light Scattering ....................................................................... 78
ix

3.3.3
3.4

Protein Delivery ..................................................................................... 79

Conclusion ..................................................................................................... 84

4. SERUM SENSITIVE PROTEIN DELIVERY BY POLYMERIC PEPTIDE
MIMICS ........................................................................................................................ 85
4.1
Introduction ................................................................................................... 85
4.1.1
Pep-1 ...................................................................................................... 86
4.1.2
PULSin .................................................................................................. 86
4.1.3
ProteoJuice ............................................................................................. 87
4.1.4
Xfect ...................................................................................................... 87
4.1.5
Protein Transduction Domain Mimics .................................................... 87
4.2

Materials and Methods ................................................................................... 88

4.3

Results and Discussion ................................................................................... 90

4.4

Conclusion ..................................................................................................... 92

5. PROTEIN TRANSDUCTION DOMAIN MIMICS FACILITATE RAPID
ANTIGEN DELIVERY INTO MONOCYTEs .............................................................. 94
5.1

Introduction ................................................................................................... 94

5.2
Materials and Methods ................................................................................... 98
5.2.1
PTDM Synthesis and Characterization ................................................... 98
5.2.2
Cell Preparation...................................................................................... 99
5.2.2.1 Whole Blood ...................................................................................... 99
5.2.2.2 Cell Lines ........................................................................................... 99
5.2.2.3 Bone Marrow ................................................................................... 100
5.2.3
Flow Cytometry ................................................................................... 100
5.2.4
Cytokine Profiling ................................................................................ 101
5.2.5
Statistical Analysis ............................................................................... 102
5.3
Results and Discussion ................................................................................. 102
5.3.1
MePh10-b-dG5-FITC Treatment of Whole Blood ................................ 102
5.3.2
Optimization of Delivery into Jurkat T Cells ........................................ 103
5.3.3
Time Survey of Peptide Delivery into Whole Blood ............................. 104
5.3.4
Concentration Survey of Peptide Delivery into Whole Blood ............... 105
5.3.5
SIINFEKL Delivery with Amphiphilic Peptides ................................... 107
5.3.6
Optimization of CpG and OVA Protein Ratio to Polymer ..................... 108
5.3.7
Co-Delivery of CpG and OVA in Whole Blood .................................... 112
5.3.8
Delivery into THP-1 Monocytes ........................................................... 114
5.3.8.1 Cytokine Response to Co-Delivery of SIINFEKL and CpG .............. 115
5.3.9
Delivery into Immature Dendritic Cells ................................................ 117
5.3.10 Delivery into Bone Marrow Derive Dendritic Cells .............................. 119
5.4
6.

Conclusion ................................................................................................... 121

PERSPECTIVES AND FUTURE WORK ........................................................... 124

BIBLIOGRAPHY ....................................................................................................... 128

x

LIST OF TABLES
Table 3.1. Molecular weight of polymer series determined by gel permeation
chromatography in tetrahydrofuran (THF) using a polystyrene standard. ............. 71
Table 5.1. Inflammatory cytokine panel for the co-delivery of SIINFEKL and CpG
using MePh10-b-dG5 into whole blood. .............................................................115

xi

LIST OF FIGURES
Figure 1.1. Categorization and progression of nanocarrier based protein delivery from
viral transfection to synthetic nanocarriers. ........................................................... 3
Figure 1.2. Single cell microinjection for introduction of exogenous proteins. ................. 4
Figure 1.3. Membrane disruption leading to transient pores that allow protein to be
delivered into the cytosol of cells........................................................................... 6
Figure 1.4. Membrane disruption using microfluidic squeezing. ...................................... 8
Figure 1.5. A simplified representation of liposomes that have one or more lipid
bilayers with an aqueous core, and solid lipid nanoparticles which have a solid
hydrophobic core. .................................................................................................. 9
Figure 1.6. (A) Color dependence on size of QDs. (B) QDs (red) colocalized with
myofibrils (green) within a cell. ........................................................................... 14
Figure 1.7. Functionalization of active proteins with super-negatively charged GFP (A)
for intracellular delivery using cationic lipids commonly used to deliver RNA
and DNA (B). ...................................................................................................... 19
Figure 1.8. Diphtheria toxin can be conjugated to cargo and brought across the cell
membrane through pH-driven pore formation releasing the cargo into the
cytosol. ............................................................................................................... 23
Figure 1.9. Schematic of synthetic nanocarriers. ............................................................ 27
Figure 1.10. Confocal microscopy of distribution of FITC-labeled anti-S100C
antibodies localized with actin (A) after delivery with the PEI cationized protein
G into HFL-1 cells (scale bar 50 µm). Delivery of a non-specific protein with
PEI-protein G resulted in unpatterned delivery (B). ............................................. 32
Figure 2.1. Polymers of interest: R8 inspired the design of dG5 (n=5), dG10 (n=10),
MeG10, PGON20, and MePh10-b-dG5. ................................................................... 41
Figure 2.2. Internalization of FITC-labeled PTDMs into HeLa cells. Cells were treated
with 5 µM PTDM for 1 hour and imaged with a CLSM (A) and assessed for
fluorescence internalization using a flow cytometer for both MFI (B) and a
positive shift in intensity from the blank (grey) in FCM histograms (C). ............. 55
Figure 2.3. Internalization of FITC-PTDMs (green) in the presence of lysotracker (red)
in HeLa cells. ..................................................................................................... 56

xii

Figure 2.4. Effects of concentration on FITC labeled polymer internalization.
Concentration dependence for MePh10-b-dG5 and R8 labeled with FITC at 5, 10,
and 20 µM (A). HeLa cells were treated with 1 hour with PTDMs and imaged
with a CLSM and assessed for MFI (B) and viability (C) using flow cytometry. .. 58
Figure 2.5. EGFP delivery into HeLa cells with unlabeled PTDMs. ............................... 60
Figure 3.1. Oxanorbornene monomers used in this study. .............................................. 75
Figure 3.2. Structures and cartoons of a polymer series with varying cationic and
hydrophobic density. ........................................................................................... 76
Figure 3.3. Structures and cartoons of the second polymer series with varying
hydrophobic density and length.. ......................................................................... 77
Figure 3.4. Dynamic light scattering curves (top) for dMe10-dG5, MePh10-dG5, and
dPh10-dG5 overlayed with their CONTIN fits (bottom) used to predict the radius
of hydration. ........................................................................................................ 79
Figure 3.5. Cellular viability after cells were treated with 2 µg of protein at a 20:1
polymer to protein molar ratio for 4 hours, as determined by 7AAD staining
compared with an untreated sample. .................................................................... 80
Figure 3.6. Representative histograms (top) compared to a blank (grey) and the
corresponding median fluorescence intensity (bottom) for EGFP delivery with
MePh10-b-MeG10, MePh10-b-dG5, dPh5-b-MeG10, and dPh5-b-dG5 into HeLa,
Jurkat T cells, and hTERT MSCs......................................................................... 81
Figure 3.7. CLSM images of EGFP delivery into HeLa cells by MePh10-b-MeG10,
MePh10-b-dG5, dPh5-b-MeG10, and dPh5-b-dG5. .................................................. 82
Figure 3.8. Representative histograms and the corresponding median fluorescence
intensity for EGFP delivery with dMe5-b-dG5, dMe10-b-dG5, MePh5-b-dG5,
MePh10-b-dG5, dPh5-b-dG5, and dPh10-b-dG5 into HeLa, Jurkat T cells, and
hTERT MSCs...................................................................................................... 83
Figure 4.1. Delivery efficiency of 2 µg GFP into Jurkats, HeLa, hTERT mesenchymal
stem cells, and human umbilical vein endothelial cells after 4 hours of treatment
in serum free conditions or complete media with amphiphilic polymers designed
for non-covalent delivery..................................................................................... 90
Figure 4.2. Viability as determined by 7-AAD of the cells treated with the proteincarrier complexes in both serum free (blue) and complete media (red). ................ 92
Figure 5.1. Processing and presentation of exogenous proteins by antigen presenting
cells. If the protein is present in the cytosol of the APC, it is processed by a
proteasome and trafficked to the ER where it is loaded through the MHC class I
pathway to prime CD8+ T cells.. ......................................................................... 95

xiii

Figure 5.2. Delivery of 2.8 µM FITC labeled polymer (A) into whole blood for 1 hour.
Cells were gated morphologically (B) and monocytes were confirmed with
CD14 staining, while granulocytes were confirmed with CD15 staining within
the respective morphological gate. ..................................................................... 103
Figure 5.3. A concentration survey for the delivery of SIINFEKL into Jurkat T cells at
varying ratios of peptide to polymer. ................................................................. 104
Figure 5.4. Delivery of fluorescently labeled SIINFEKL complexed with PTDM at a
ratio of 1:10 into whole blood for 15, 30, 45, and 60 minutes............................. 105
Figure 5.5. (A)Delivery of fluorescently labeled SIINFEKL complexed with PTDM at
a ratio of 1:10 into whole blood at peptide concentrations of 0.25, 0.5, 1, and 2
µM of peptide.................................................................................................... 106
Figure 5.6. Delivery of fluorescently labeled SIINFEKL into whole blood using the
well known cell penetrating peptides pep-1 and R9 in comparison with MePh10b-dG5 after 1 hour incubation. ........................................................................... 108
Figure 5.7. Optimization for delivery of CpG-FITC and Ovalbumin (OVA-AF647) in
Jurkat T cells to determine the optimal ratio of cargo to polymer. ...................... 110
Figure 5.8. Optimization of co-delivery of 100 nM CpG-FITC and 50 µM OVA-AF647
into Jurkat T cells. ............................................................................................. 111
Figure 5.9. Co-delivery of CpG-FITC and OVA-AF647 complexed with MePh10-bdG5 into whole blood. Increasing concentrations of CpG were used (50, 100, and
200 nM) along with 50 nM OVA protein.. ......................................................... 113
Figure 5.10. Co-delivery of SIINFEKL and CpG with MePh10-b-dG5 compared with
cytokine treatment to differentiate monocytes into dendritic cells. ..................... 114
Figure 5.11. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) into THP-1 cells
using MePh10-b-dG5. Upregulation of activation surface markers (C) on THP-1s
24 hours after delivery of polymer-antigen-agonist complexes. ......................... 116
Figure 5.12. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) using MePh10-bdG5 into immature dendritic cells derived from the THP-1 cell line.. ................. 118
Figure 5.13. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) using MePh10-bdG5 into immature dendritic cells derived from C57BL/6 mouse bone marrow. . 120

xiv

GLOSSARY
7-AAD
APC
BMDC
CD11c
CD209
CD4 T cell
CD40
CD8 T cell
CD80
CD86
CLSM
CpG
CPP
CPPM
CTL
DC
DCM
dG
DMAP
dMe
DMF
DMSO
DNA
dPh
EDC
EGFP
FBS
FSC
G3
GFP
GPC

7-Amino-actinomycin D
Antigen Presenting cell
Bone Marrow Dendritic Cell
Dendritic cell surface marker
DC-sign: dendritic cell surface marker
Helper T cell
Surface marker on APCs
Cytotoxic T cell
Costimulatory surface marker on APCs
Costimulatory surface marker on APCs
Confocal Laser Scanning Microscopy
TLR-9 agonist
Cell penetrating peptide
Cell penetrating peptide mimic
Cytotoxic T Lymphocyte
Dendritic Cell
Dichloromethane
Di-guandine monomer
4-Dimethylamnopryridine
Di-methyl monomer
N,N-dimethylformamide
Dimethyl sulfoxide
Deoxyribonucleic Acid
Di-phenyl monomer
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
Enhanced Green Fluorescent Protein
Fetal Bovine Serum
Forward Scatter
Grubb's 3rd generation catalyst
Green Fluorescent Protein
Gel permeation chromatography

H-2Kb
HLA-DR
iDC
IFN
IL
LPS

Antibody against presentation of SIINFEKL in MHC I
Human MHC class II subtype
Immature Dendritic Cell
Interferon
Interleukin
Lipopolysaccharide
xv

MeG
MePh
MFI
MHC
MHC class I
MHC class II
MSC
NMR
OVA
PBS
PTD
PTDM
R9/R8
RBCs
ROMP
SEM
SIINFEKL
SSC
TFA
THF
THP-1
TLR
TNF

Methyl-guanidine monomer
Methyl-phenyl monomer
Median Fluorescence Intensity
Major Histocompatibility Complex
Present on every cell type, interacts with CD8 T cells
Only presented on APCs, interacts with CD4 T cells
Mesenchymal Stem Cells
Nuclear Magnetic Resonance
Ovalbumin
Phosphate Buffered Saline
Protein Transduction Domain
Protein Transduction Domain Mimic
Nona-arginine, octarginine
Red Blood Cells
Ring-Opening Metathesis Polymerization
Standard Error of the Mean
MHC Class I specific Antigen from Ovalbumin
Side Scatter
Trifluoroacetic acid
Tetrahydrofuran
Human Monocyte Cell Line
Toll Like Receptor
Tumor Necrosis Factor

xvi

CHAPTER 1
INTRACELLULAR DELIVERY OF FUNCTIONAL PROTEINS
1.1

Introduction
Proteins and antibodies have the capacity to perform specific and complex

functions making them promising candidates to probe molecular pathways within cells.
Most proteins that would facilitate these specific interactions are generally incapable of
passive diffusion across the cell membrane due to their size and polarity. Additionally,
physical and chemical changes extracellularly and intracellularly can alter a proteins
function via hydrolysis, oxidation, proteolysis, and denaturation.1 To address these issues,
a wide variety of delivery methods and vehicles have been designed for transporting and
protecting these complex cargos.
Historically, introducing exogenous protein into the cell has been accomplished
indirectly by delivering DNA that will express the protein of interest into the cell or by
controlling protein synthesis through the delivery of RNA.2 Despite the utility of these
approaches, direct protein delivery has several advantages over recombinant genetic
approaches. Instead of genetically manipulating cells to express a protein of interest, which
can result in random insertion and mutation of endogenous genes, protein delivery allows
for temporal control into specific areas of the cell. The delivery of proteins like Cre
recombinase and the CRISPR-Cas9 system allow for specific gene editing with high
specificity and low toxicity.3,4 The transient nature of the protein within the cell also means
that the amount of protein and its function can be controlled and is not indefinite. In
comparison with small molecule drugs, the targeted effect can be exceptionally specific,
such as in the case of using antibodies to promote or interrupt intracellular pathways.5
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Currently, the overarching term attributed to methods of protein delivery is
transduction which is rooted in its use for viral delivery of genetic material. While the field
of protein transduction began with the use of physical membrane disruption such as
electroporation and microinjection, it has shifted more towards the use of lipids, peptides,
and synthetic nanocarriers to facilitate the transport of proteins across the membrane.6
Additionally, a variety of inorganic carriers are also being developed as theranostic
delivery reagents.7–9 An overview of these methods is provided, with specific attention on
their ability to deliver functional proteins into cells.
The major design principles of nanocarriers are three-fold: they need to (a) package
and protect cargo, (b) deliver the protein intracellularly, and (c) release payload with
appropriate spatiotemporal dynamics. One of the major areas of debate for transduction is
the mechanism through which these carriers cross the membrane.6,10,11 The mechanism of
cellular entry directly dictates the availability of the cargo within the cell. If most of the
nanocarrier assemblies are taken up through endocytosis, the cargo must overcome the
endosomal membrane before being readily available in the cytosol or nucleus.
The field of nanocarriers is extremely complex and correct definitions of each
carrier type are essential for comparing to other systems within the same class and for the
translation of essential concepts to the next generation of carriers.12 Here, we propose
classification guidelines to help define carrier types. Although some overlap between the
different categories is possible, as indicated in Figure 0.1, usually the distinction is clear
enough to choose a predominant label.
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Figure 0.1. Categorization and progression of nanocarrier based protein delivery
from viral transfection to synthetic nanocarriers. The circumference of the circle
roughly indicates the volume of research directed toward protein delivery.
The scope of this introduction is to explore the methods that facilitate the transport
of functional proteins across the cell membrane with special attention to nanocarrier types.
While many methods explore protein delivery using fluorescently labeled cargo, the focus
here is largely on in vitro experiments with functional protein cargo that has some
measurable intracellular biological activity. This introduction highlights the current
approaches to functional protein delivery along with the existing challenges and offers
some perspective into future directions for the field.

3

1.2

Physical Delivery Methods

1.2.1 Microinjection
Microinjection involves the use of a glass micropipette to deliver foreign material
with extremely precise spatial and temporal control into a variety of cell types.13,14 A
schematic of a single cell being microinjected is shown in Figure 0.2. Since the only
exogenous material is the controlled amount of injected substance, it is theoretically the
only independent variable in well controlled experiments.15 Microinjections can be
performed directly into both the cytosol and the nucleus, requiring much less protein than
electroporation or carrier based methods.14 Additionally, specific cell types can be
transduced without using targeting motifs. Dosage of multiple cargos can also be controlled
with current models of air-pressure-driven micro-injectors, which allow fine tuning of
injection pressure and timing.14

Figure 0.2. Single cell microinjection for introduction of exogenous proteins. Figure
adapted from By KDS444 via Wikimedia Commons (left) and Stewart et. al.6 (right).
Microinjection has been extensively used in studies with primary human neurons,
since they are difficult to transfect by other methods. Several examples of functional
protein delivery exist including recombinant caspases, heat shock protein 70 (Hsp70), and
antibodies.16–19
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Direct microinjection of recombinant active enzyme capsase-6 induces a protracted
course of apoptosis in neurons. The results show that active caspase-6 induces significant
cell death in neurons but not in astrocytes, where caspase-3 triggers cell death in astrocytes
and not in neurons.16
Amyloid-b (Ab), an intracellular peptide related to Alzheimer’s disease is
extremely toxic to human primary neurons when injected into the cytosol but not when
applied in culture medium suggesting intracellular Ab may contribute to cell death more
significantly than extracellular Ab.17 Co-microinjection of Hsp70 with intracellular Ab
blocks the toxicity of the Ab suggesting that estrogens and androgens protect neurons
against Ab toxicity by increasing the levels of Hsp70.
Microinjection of antibodies was used to study the importance of actin filaments
for the regulation of gap junctional intracellular communication in astrocytes.19 The
injection of the antibody reduced spreading of neurobiotin suggesting that the actin
cytoskeleton is involved in the regulation of intracellular communication.
Although microinjection has low cytotoxicity, only a few hundred cells can
reasonably be transduced at a time limiting the overall efficacy of this technique.16,17
Positive controls and immune-histochemical staining can be used to detect the transduction
of injected proteins. Additionally, with division, delivered proteins will be diluted out with
each cell cycle resulting in a lower readout for the injected protein in rapidly dividing cell
types. Lastly, the injection causes physical stress to the membrane of the cell. Therefore a
vehicle control is required to monitor assess the effect of the injection on viability.20
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1.2.2 Electroporation
Electroporation uses an electric field to create short-lived pores through the cell
membrane, which allow external molecules to cross.6,21 Membrane disruption, as
illustrated in Figure 0.3, allows small and large molecules such as antibodies, proteins, and
DNA to be delivered through these reversible pores. There are several advantages to
electroporation including its ease of use, as well as avoidance of endosomal entrapment.
Additionally, it eliminates the cytotoxicity associated with foreign materials in the cases of
chemical transduction or viral infection.

Figure 0.3. Membrane disruption leading to transient pores that allow protein to be
delivered into the cytosol of cells. Illustration adapted from Steward et. al.6
Traditionally, a solution with suspended cells is dispersed between parallel plates
that apply a series of electrical pulses of determinable voltage, frequency, and duration.21
Microfluidic designs offer the ability to localize the electric field to the scale of the cell,
reducing the required voltage, and providing better heat dissipation.6,22
A notable example is the transduction of Cas9:sgRNA complexes via
electroporation into primary human hematopoietic stem cells and T cells resulting in
specific nucleotide insertions in the CXCR4 and PD-1 surface receptor genes.23 Direct
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protein delivery via electroporation improved efficiency and reduced off target effects
compared with endogenous expression of Cas9.23,24 Other examples of proteins that have
been transduced into a variety of lymphoid cells include cytochrome c, caspase-8, and
granzyme B, all which showed functional status in the major apoptosis pathway of intact
cells.25
When compared directly with a lipid-based system, transduction of rEGFP was
approximately 10% at 18 hours after electroporation compared with about 20% efficiency
from the lipid based system.26 Increased voltage and protein concentration increased
transduction efficiency, though never exceeded 30% in the study. While efficiency can be
high for electroporation depending on the size of the cargo, it also results in membrane
damage leading to excessive cell death, especially with sensitive cell, such as primary
cells.27 Additionally, the electric field can have detrimental effects such as aggregation and
denaturation on both the biomolecules being delivered, as well as endogenous cellular
proteins.28,29
1.2.3 Microfluidics
Cytosolic delivery has also been reported using rapid mechanical deformation on a
microfluidic platform.30 As the cell passes through a constriction with a minimum
dimension smaller than the cell diameter, as seen in Figure 0.4, it results in the formation
of transient pores.31 The size and frequency of the pore is dependent on the shear and
compressive forces caused by the microfluidic channel. The pores allow for material from
the surrounding media to diffuse into the cytosol and cells can be processed at a rate of
20,000 cells/s.31
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Figure 0.4. Membrane disruption using microfluidic squeezing. The intact cell is
passed through a narrow channel which causes pores to form allowing exogenous
protein (yellow) to cross the membrane. Image adapted from Stewart et. al.6
Transcription factors (Oct4, Sox2, c-Myc, and Klf-4) were delivered to human
fibroblasts yielding higher levels of protein expression compared with other delivery
methods that rely on endocytosis.31 Cytoplasmic delivery of quantum dots can also be
achieved using high throughput microfluidic devices.32
Microfluidic membrane disruption has most recently been use to load antigens into
polyclonal B cells for use as cellular vaccines.33 Post transduction, the B cells elicited
robust priming of effector cells in vitro conferring cytosolic delivery OVA protein
indicating successful transduction. Higher flow rates result in higher uptake, but also cause
higher cytotoxicity. Microfluidics is only useful for transducing cells in suspension and has
lower overall efficiency than Lipofectamine, but it does result in higher levels of cytosolic
delivery.31
1.2.4 Insight
Physical membrane disruption addresses many challenges associated with protein
delivery. Traditionally, key weaknesses of membrane disruption strategies have been the
inconsistent extent of plasma membrane injury from cell-to-cell. In general, these methods
render insufficient delivery and cause excessive cell damage. Membrane disruption also
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suffers from poor throughput or scalability, loss of cytoplasmic content, and slow cell
recovery resulting in inefficient protocols.6 Methods that employ electric fields may
denature proteins or damage cell components and many physical disruption techniques also
require cells to be in suspension.
1.3

Lipid-Based Nanocarriers

1.3.1 Liposomes
Conventional liposomes are composed of phospholipids and cholesterol, forming a
spherical vesicle with one or more bilayers (Figure 0.5). For several decades, liposomal
carriers have been widely used for the delivery of various biomolecules including proteins,
antibodies, peptides, and nucleic acids either through encapsulating cargo in the liposome
or embedded it on the membrane surface.34–37 The liposomal bilayer stabilizes the cargo by
preventing degradation and facilitates internalization into cells generally through
incorporation of cationic charge in the lipid membrane. Compatibility of constituent lipid
components with the cell membrane make liposomes attractive for many applications.34,38

Figure 0.5. A simplified representation of liposomes that have one or more lipid
bilayers with an aqueous core, and solid lipid nanoparticles which have a solid
hydrophobic core.
Cellular uptake of liposomes is generally believed to be mediated by endocytic
processes resulting in entrapment in endosomal compartments within the cell.39 To
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overcome the endosomal barrier, several strategies have been used including pH sensitivity
and the addition of cell penetrating peptides to the surface of the liposome.40
An example of functional protein delivery mediated by a cationic lipid is the use of
RNAiMAX™ to deliver CRISPR-Cas9 proteins along with their single guide strand RNA
with over 50% gene editing efficiency.3 Another bio-reducible lipid system has also shown
delivery of the CRISPR-Cas9 complex and subsequent genome editing.41
Liposomes with protein suspended in the membrane, known as proteoliposomes,
have also been used to deliver mitochondrial VDAC and Bak, which are important stimuli
in the release of cyt-c and caspase activation, ultimately resulting in apoptosis.36 A potent
primary CTL response against soluble protein can be achieved through the delivery of
antigen, such as OVA, in pH-sensitive liposomes to dendritic cells.42 Efficient MHC class
I presentation of antigens has also be shown using liposomes decorated with octaarginine.35,43
Liposomal systems are widely studied and tend to be a benchmark in the field of
biomolecule delivery due to their tunability and ease of use. In addition to their high
endosomal entrapment, liposomal preparation methods which use solvents, sonication, and
detergents can lead to protein denaturation and loss of activity. High cellular toxicity may
also occur due to treatment in the serum free conditions which are required for efficient
delivery, making liposomes an unfavorable candidate for sensitive cell types such as
primary cells.44
1.3.2 Solid Lipid Nanoparticles
Solid lipid nanoparticles (SLNs) are submicron colloidal particles with a rigid core
composed of hydrophobic solid lipids stabilized by an emulsifying layer in an aqueous
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dispersion (Figure 0.5). In general, SLNs are solid at room or body temperature and both
hydrophobic and hydrophilic proteins can be incorporated or adsorbed to their surface
resulting in improved stability and sustained release of the cargo.45 The main factors
influencing peptide and protein release from solid lipid particles are the physiochemical
characteristics of the loading, particle size, lipid matrix composition, and choice of
surfactants.46 Functional proteins including insulin, somatostatin, and thymocartin have
been incorporated into SLNs through solvent evaporation, micro-emulsion, or melt
dispersion with varying rates of loading and subsequent release.47,48
The hydrophilic nature of most proteins reduces their ability to be
microencapsulated into the hydrophobic matrix of SLNs as they tend to partition in the
water phase during the emulsion preparation.46 Additionally, processing conditions can
lead to aggregation or denaturation of cargo like their liposome counterparts. Lipid carriers
with several lipids and emulsifying agents generally exhibit low cytotoxic effects in vitro
compared with their polymeric counterparts, even at high concentrations. The cytotoxicity
of SLNs can be mainly attributed to components of the aqueous phase, especially non-ionic
emulsifiers and preservatives.49
1.3.3 Insight
Although protein encapsulation within lipid delivery systems can protect peptides
and proteins from proteolytic enzymes, low protein loading efficiency and slow endosomal
escape remain major hurdles for lipid delivery systems. Due to their synthetic simplicity
and wide spread use, lipid-based carriers remain one of the most predominant carriers in
the field of delivery. In the future, we can expect an increasing number of lipid-based
carrier systems, especially for proteins with poor aqueous solubility.
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1.4

Inorganic Nanocarriers

1.4.1 Carbon Nanotubes
Carbon nanotubes (CNTs) are cylindrical allotropes of carbon that have a long
hollow structure with walls formed by a single layer of carbon, also known as graphene.
Their orbital hybridization imparts distinct properties including exceptional strength and
allows for an exceptionally high length to diameter ratio.50,51 CNTs offer several appealing
features such as large surface areas with well-defined physical and chemical properties, as
well as unique optical and electrical properties.52 Biomolecules can be conjugated noncovalently or covalently to the surface, helping to reduce their toxicity and
immunogenicity.50–54 While there have been significant advances in the field of CNT-based
drug delivery, there are only a few examples of biomolecules being delivered into cells.
Kam et al. delivered streptavidin, a protein with clinical applications in anticancer
therapies, conjugated to single walled nanotubes (SWNTs) into 3T3 fibroblasts, CHO,
HL60, and Jurkat T cells, showing uptake through endocytosis. Additionally, they report
streptavidin concentration dependent cytotoxicity, but negligible cell death caused by the
SWNTs without streptavidin.51
Experiments exploring the binding, intracellular transporting, and release of
cytochrome c (cyt-c) with SWNT carriers were carried out in an investigation of biological
function. Due to its low molecular weight, SWNTs have a high loading of cyt-c, which is
known to activate apoptosis and activity was monitored using Annexin V staining. HeLa
and NIH-3T3 cells showed increased rates of apoptosis in the presence of cyt-c SWNTs
suggesting that cyt-c was still functional after being transported into the cell.55
Additional reports have investigated functionalization with peptide chains to show
delivery of shorter sequences. Although peptide function is not explicitly demonstrated,
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high levels of cell death are shown after delivery of a peptide known to block the beta
adrenergic receptor conjugated to CNTs.54
CNTs face challenges regarding (1)

synthesis:

purity, bioconjugation,

functionalization, and modification that allow biocompatibility; (2) a thorough
understanding of mechanism and interaction with cells; (3) development of toxicity
guidelines and analysis; and (4) demonstration of advantages compared with existing
technologies.50 Cytotoxicity associated with CNTs remains a major concern both in vitro
and in vivo. Conflicting reports may be attributed to variability in the dose, purity,
functionalization, cell type, and treatment methods.50 The use of metal catalysts remains
the main source of cytotoxicity followed by their tendency to aggregate.51,54 More
guidelines and systematic testing are required to determine toxicity and the life cycle of
functionalized CNTs within cells to further their viability for use in biomolecule delivery.
1.4.2 Quantum Dots
Quantum dots (QDs) are nanocrystals on the order of 2 to 10 nm made of
semiconducting materials that can fluoresce to produce distinctive colors dependent on the
size of the particle.56 The distribution of colors and sizes are shown in Figure 0.6A. Due to
their small size, QDs have been widely used as fluorescent probes to visualize biological
processes both in vitro and in vivo due to their narrow tunable emission spectra, excellent
thermal stability, and resistance to photo-bleaching.57
The delivery of QDs and their protein cargos can be roughly divided into passive
endocytosis or carrier facilitated uptake, the latter of which involves conjugation to a
peptide, protein, or polymer.58,59 Most QD-protein conjugates without an endosomal
escape motif are distributed in endosomal compartments making their cargo not readily
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accessible in the cytosol.57 QDs are not the most efficient functional protein nanocarrier,
but do allow for dynamic tracking and detection of exogenous proteins and peptides within
cells.60
QD-based transduction has been explored using the exogenous thin filament protein
cardiac troponic C (cTnC) into myofibrillar cells.61 To facilitate membrane crossing and
endosomal escape, a peptide linker TAT-HA2 was conjugated to the QD-cTnC.
Internalization and distribution through the cell, specifically in association with myofibrils,
as seen in Figure 0.6B, was achieved with post-functionalization with the peptide.

Figure 0.6. (A) Color dependence on size of QDs. (B) QDs (red) co-localized with
myofibrils (green) within a cell. Figure adapted from Zrazhevskiy et. al.57and
Koshman et. al.61
Intracellular delivery of QD-protein conjugates is highly dependent on the nature
of the QD itself, as well as the cell type being investigated. Current techniques to
functionalize QDs are dependent on the QD and are not easily translatable across cargos.62
Additionally, conjugation as well as a shift in pH can increase the size of the QD
substantially.62 The toxicity of QD materials also remains a concern, arising from the
semiconducting metals.63 While there have been many accomplishments in the
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development of controlled delivery of QDs into cells, progress in functionalization and
cytotoxicity will help propel the use of QDs as visualization aids in cell culture.
1.4.3 Gold Nanoparticles
Gold nanoparticles (AuNPs) are easily functionalized yet bio-inert, facilitating
cellular imaging with low cytotoxicity.64,65 Similar to QDs, AuNPs require surface
functionalization with cationic amines or peptides to promote endocytosis, or antibodies
for receptor mediated endocytosis. Alternatively, reports of citrate capped AuNPs have
also shown internalization by cells, possibly caused by protein adsorption.66
Recently, spherical hierarchical self-assemblies between proteins and AuNPs have
been used to deliver functional proteins into cells.67,68 Proteins were tagged with an oligoglutamic acid (E10), which can self-assemble with arginine functionalized AuNPs
resulting in direct cytosolic delivery of proteins with a variety of sizes and charges into
mammalian cells while maintaining their function. Most notably, Cre recombinase, a gene
modifying protein, was delivered into a LoxP modified human embryonic kidney cells
resulting in knockout of an RFP gene and subsequent expression of GFP after 48 hours.69
Additionally, granzyme A, a cytolytic enzyme produced by cytotoxic T cells, was delivered
into HeLa cells via the same strategy, resulting in caspase 3/7 mediated cell death.67
In terms of vaccine development, Wang et. al. designed a multivalent antigen and
adjuvant co-delivery platform using both click chemistry and chelation of AuNPs to attach
the cargo.64 Both types of conjugation induced production of pro-inflammatory cytokines
and led to antibody production against the delivered antigen. AuNPs have also been used
to deliver recombinant human VEGF, where the protein was attached by the thiol group of
cysteine residues.70 HUVECs treated with the AuNP-VEGF proliferated substantially
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faster than those without the growth factor. While functionalization or protein modification
is required, gold nanoparticles provide a useful tool for in vitro delivery, as well as
intracellular imaging for protein tracking and dynamics.
1.4.4 Silica Nanoparticles
Mesoporous silica nanoparticles (MSNs) are prepared by an assembly of silicates
and surfactant, in which the pore size and structure are easily controlled by the co-assembly
conditions. In general, MSN materials have large surface areas and pore volumes and can
by endocytosed by mammalian cells making them effective delivery vehicles for the
controlled release of biomolecules.71–73 Internalization studies suggest that the MSNs
undergo nonspecific adsorptive endocytosis, and endosomal uptake was shown using FITC
labeled cargos.74 The addition of amine or guanidine groups, such as cell penetrating
peptides, enhances energy dependent uptake and promotes endosome escape.74,75
To show functional protein delivery using MSNs, cyt-c was delivered into HeLa
cells.76 The protein was loaded using a diffusion driven process based on concentration and
controlled release was measured with a drop in pH consistent with that which occurs in
lysosomes. Delivery into HeLa cells revealed release of the functional protein into the
cytoplasm. Loading and release of the cyt-c relied on its interactions with the silica surface
and may not be easily applied to other proteins. Another example of functional protein
delivery was MSNs functionalized with n-octadecyltrimethoxysilane were loaded with
Ribonuclease A and anti-phospho-Akt antibody, which were subsequently delivered into
MCF-7 human breast cancer cells resulting in controlled apoptotic cell death. 77
A recently developed system involves a breakable hybrid organo-silicananocapsule where the protein cargo is encapsulated within a breakable hybrid shell
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comprising of disulfide bridges embedded in a silica network.78 The cytotoxic protein
human TRAIL Apo2 ligand and onconase were delivered into C6 glioma cells where the
active proteins were released by breaking the shell of the capsule. However, as shown
through co-localization between lysotracker and GFP, much of the protein cargo remains
sequestered in lysosomes with very little being available in the cytosol.
Although pores in MSNs can be used to encase proteins, there is a size limit
restricting larger proteins from being successfully loaded and transported across the
membrane.79 Progress in controlling pore size and morphology will facilitate
immobilization of a larger variety of cargos.
1.4.5 Magnetic Nanoparticles
The ability to tune the surface of magnetic nanoparticles (MNPs) makes them
multifunctional, allowing synthesis with a variety of cargos.80 Magnetically mediated
protein delivery can enhance the therapeutic profile by increasing the localized
concentration of target cargo and minimize non-specific interactions. Although MNPs have
shown application in theranostics, there are very few cases of the use of MNPs for
functional protein delivery in vitro.
Intracellular delivery of MNPs loaded with catalase, an antioxidant enzyme, was
confirmed through the rescue of target cells that were undergoing toxicity due to hydrogen
peroxide.81 Experiments were performed in bovine aortic endothelial cells, where the
MNPs were guided to these cells and increased their resistance to oxidative stress.
Iron oxide nanoparticles have been shown to cause cell membrane injury in both a
concentration and time dependent manner.82 Therefore, low concentrations of MNPs are
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optimal to ensure mitigation of oxidative stress induced cell injury. Additionally, cargo
must be functionalized to the MNP, potentially reducing the functionality of the protein.
1.4.6 Insight
Since inorganic nanoparticles are relatively new to the field of biomolecule
delivery, many hurdles are still being addressed such as aggregation. Additionally, due to
their inert nature many inorganic nanoparticles require functionalization with other
delivery vehicles such as a cell penetrating peptide or cationic polymers to achieve
internalization. The theranostic benefits of inorganics, especially when used as imaging
agents has huge potential, but for now these particles are not able to deliver functional
protein intracellularly.
1.5

Protein and Peptide Mediated Carriers

1.5.1 Engineered Proteins
Supercharged proteins are a class of engineered or naturally occurring proteins with
unusually high net positive or negative theoretical charge.83 The creation of supercharged
proteins was first reported in 2007 as the product of extensive mutagenesis in which solvent
exposed residues on the proteins surface are substituted with either acidic or basic amino
acids.84 The functionality of these proteins is preserved, but reduced in some cases.83 Both
positively and negatively supercharged proteins exhibit a remarkable ability to withstand
thermal or chemical induced aggregation.84,85 Superpositively charged proteins are also
able to penetrate mammalian cell membranes and have shown utility in enabling the
delivery of functional proteins.83,85,86
Positively supercharged GFP has been shown to deliver a variety of functional
proteins directly into cells by translational fusion.85,87 Cre recombinase functioned as a
general measure of delivery as its enzymatic activity is only observed by its presence in
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the nucleus. In addition to Cre recombinase, functional delivery of the CRISPR-Cas9 gene
editing system has been shown using supernegatively charged GFP in conjunction with the
cationic lipid system RNAiMAX.3 The strategy for fusing functional proteins to the
negatively charged GFP is illustrated in Figure 0.7.Recently, a diverse class of naturally
occurring supercharged human proteins has been identified that potentially deliver
functional proteins into mammalian cells.83

Figure 0.7. Functionalization of active proteins with super-negatively charged GFP
(A) for intracellular delivery using cationic lipids commonly used to deliver RNA and
DNA (B). Image adapted from Zuris et. al.3
In addition to supercharged proteins, intracellular delivery has been reported for
engineered G proteins which contain a histidine affinity tag on the N- terminus and cell
penetrating peptide sequence at the C-terminus.88 The engineered G protein allows for
capture of surface modified nanoparticles and antibodies through non-covalent interactions
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with the histidine tag and non-invasively delivers the complex into cells using the CPP.
Delivery of both cargos independently and combined was demonstrated in Hela cells.
The non-viral E2 subunit of pyruvate dehydrogenase has also been developed as a
protein delivery platform.89,90 E2 is a caged protein made of self-assembling monomers to
form a hollow capsule which can be post modified with proteins. E2 was shown to codeliver the MHC I restricted peptide SIINFEKL and CpG, an oligonucleotide into dendritic
cells.89
Supercharged proteins are an interesting, new class of protein delivery vehicles.
Understanding how these proteins are able to cross the membrane would facilitate the
development of specific targeted carriers. Additionally, movement away from covalent
attachment would enable these proteins to be easily used with a variety of cargos.
1.5.2 Exosomes
Exosomes are a family of vesicles secreted by most cell types with a diameter in
the range of 30-120 nm.91 The production of exosomes is a major route of cellular excretion
allowing for the disposal for the removal of unwanted RNA and proteins and can also
transport cargos between cells. Initially, an invagination of endosomal membranes creates
a multi-vesicular body, they are then fused with the membrane and secreted.91 Exosomes
have shown utility in therapeutics due to their low immunogenicity and toxicity but high
biological permeability and biocompatibility.92
Due to their intrinsic ability to carry endogenous proteins, exosomes seem to be
suitable carriers for protein delivery. An example of this endogenous protein transfer was
demonstrated by Shimoda et al. who reported the functional transfer of CagA into recipient
cells inducing cell elongation.93 Recently, the gene editing protein Cre recombinase was
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loaded into exosomes by exploiting the evolutionarily conserved late-domain and showed
functional gene knockdown.94
Loading and delivering small RNAs has been a major focus using exosomes for
biological delivery.91 There have been only a handful of reports on successful packaging
of macromolecular proteins into exosomes due to the major challenge of low loading
efficiency.93–96 There is a need to explore more efficient protein loading approaches before
exosomes will be widely applied for protein delivery.
1.5.3 Virus Like Particles
Virus like particles are derived from viral capsid proteins and resemble their native
virus counterpart, but lack the genetic components.28,97,98 They can be assembled to
encapsulate a variety of non-viral biomolecules including proteins and engineered to
express and display heterologous proteins. Many viruses can be used as VLPs including
murine leukemia virus, lentivirus, retrovirus, Sendai virus, and their ability to deliver
bioactive proteins such as antibodies, transcription factors, and enzymes has been
demonstrated in a variety of cell types.99–102 Although some viruses possess natural cell
and tissue tropism,103 broad cell specificity is exhibited by many VLPs making them viable
candidates for protein delivery into a variety of cell types.28
Kaczmarczyk et. al. have shown that VLPs can be used to deliver a variety of
functional proteins intracellularly, including Cre recombinase, cytotoxic enzymes, and
human caspase 8.97 Protein ligands such as TRAIL and IFN-g can also be displayed on the
outside of the VLP allowing for signaling control within cells during delivery.97
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Similar to liposomes and exosomes, controlled loading of specific proteins into
VLPs remains a challenge. Additionally, some knowledge of molecular biology is required
to use this in a functional laboratory setting to load proteins of interest into the VLPs.
1.5.4 Protein Toxins
Plant and bacterial toxins can be potent inhibitors of intracellular processes and
often contain their own translocation domain or complex.39,104 While some toxins exploit
cellular machinery to enter cells such as the cholera toxin, others can form pores for
cytosolic entry like anthrax and diphtheria.105–108 In general, pore forming toxins are an
ensemble of an enzymatic moiety in conjunction with a cell surface receptor that mediates
entry into the cytosol.104 These protein complexes can be exploited for protein delivery,
though the toxins themselves can have detrimental effects on cellular function, as well as
viability.104
Anthrax has been shown to deliver a variety of cargos including peptides, proteins,
and antibody-like molecules with varying degrees of success.105 Ballard et. al. modified
cytotoxic T cell epitopes derived from bacteria with an anthrax derivative to create
immunogenic response for mouse CD8 T cells.106 Additionally, the delivery of an antibody
mimic into the cytosol of cells via conjugation with anthrax into has been demonstrated by
co-immunoprecipitation of the affibody with its target, as well as interruption of several
pathways.109
Auger et. al. demonstrated that a variety of proteins could be delivered using the
diphtheria toxin.110 The conjugation, targeting and endosomal escape of their strategy is
depicted in Figure 0.8. To ensure that the protein cargo is functional after conjugation to
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the diphtheria, alpha-amylase was delivered into HEK293 cells resulting in rapid glycogen
degradation in treated cells.

Figure 0.8. Diphtheria toxin can be conjugated to cargo and brought across the cell
membrane through pH-driven pore formation releasing the cargo into the cytosol.
Figure adapted from Auger et. al.110
Biological toxins provide a facile delivery platform for biomolecules with diverse
structures and functionalities due to the promiscuity of their pore forming units.
Investigations by several groups have demonstrated that the cargo must be able to adopt an
unfolded or extended conformation in the endosome and cargos with low pKa values that
cannot be protonated in the endosome may inhibit translocation limiting the variety of
cargo that can be efficiently transduced.105 Lastly, further exploration in to the
immunogenicity and cellular effects of using toxins would provide more insight into the
practical use as protein carriers.
1.5.5 Cell Penetrating Peptides
Initially introduced into the field of delivery over two decades ago, cell penetrating
peptides have become a staple for the intracellular delivery of proteins and other
biomolecules.111–113 The ability to transverse the membrane has transcended their use
across a variety of systems including liposomes, engineered proteins, and polymers.113–115
The hallmark discovery of HIV-1 Tat lead to the discovery and generation of an entire field
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of short, cationic, and sometimes amphiphilic peptide sequences.11,112,116,117 These can be
loosely divided into naturally occurring sequences such as Antennapedia homeodomain
and MAP; chimeric mimics like transportan and penetratin; along with their synthetic
peptide mimics including R9 and Pep-1. 11,118
Intracellular delivery can be achieved through direct conjugation of cell penetrating
peptides to the cargo requiring post modification of the desired cargo. Some studies have
reported non-covalent complexing with the desired cargo.119–121 An inexhaustible list of
protein delivery using cell penetrating peptides exists; a few highlights have been included
here.
R9 has been used in to co deliver covalently linked Cas9 protein along with guide
strand RNA to show efficient knockdown by the functional ribonuclear protein complex.122
Additionally, oligo arginine attached to zinc finger nucleases as well as TALEN proteins
have also shown gene editing capabilities suggesting their presence in the nucleus with low
cytotoxicity.123
One major example of TAT and other CPPs is its use in delivering peptides and
proteins for cancer treatments. Fusion of the apoptosis inducing protein apoptin to HIVTAT resulted in high transduction efficiency in all cell types, but only apoptosis in cancer
cells after migration to the cytoplasm and nucleus.124 Other proteins include p53, anti-p21,
and antitumor antibody fragments.125 TAT fusion proteins have also been shown to deliver
hsp70, required for protection against glutamate dehydrogenase deficiency disorders.126,127
Endosomal escape remains a major concern for many cell penetrating peptide
systems. Akishiba et. al. demonstrated delivery of Cre recombinase, saporin, and IgG in
addition to exosome encapsulated proteins using a modified endosomolytic peptide derived
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from the spider venom.96 Cytosolic delivery of bioactive protein was confirmed with gene
recombination by Cre recombinase. The delivered anti-glucocorticoid receptor IgG
blocked intracellular signaling and transcription suggesting functional activity of the
antibody in the cytosol.
Conjugation of CPPs to biomolecular cargo has proven an effective tool for protein
delivery, but there are still challenges within the field including toxicity, stability, and
immune response.128,129 Additionally, post modification of the cargo with CPPs can
influence the functionality of the protein within the cell.
1.5.6 Insight
Natural sources of protein delivery such as CPPs and VLPs provide a biological
answer to protein delivery. Since all the components are naturally synthesized by cells,
degradation products are of minimal concern making these systems extremely
biocompatible. Like all delivery systems, some assembly is required and in many cases
knowledge of molecular biology methods is useful to facilitate conjugation or entrapment
of the protein.
1.6

Synthetic Polymeric Nanocarriers

1.6.1 Protein Transduction Domain Mimics
Polymers can be used to mimic the functional transduction domains of proteins
either by polymerizing cationic and hydrophobic monomers, or by incorporating active
motifs into the backbone of the polymer chain.114,115 Several groups have developed
systems for protein transduction domain mimics (PTDMs), also referred to as cell
penetrating peptide mimics (CPPMs).130–132
As a developing area of delivery, PTDMs have mostly been explored for uptake
using a fluorescent label on the polymer itself. The Kolonko et. al. has demonstrated
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cytosolic and endosomal uptake of FITC labeled artificial translocation domain.133
Additionally, McKinlay et. al. show that uptake of guanidinium-rich oligophosphoesters is
superior to their guanidinium-rich oligocarbonates and oligoarginines counterparts.131
Using a norbornene based amphiphilic block copolymer, Sgolastra et. al.
demonstrated non-covalent delivery of functional Cre recombinase into a human T cell line
using PTDMs resulting in gene knockout.134 A similar polymer was used for delivery of
functional anti-pPKCq into primary human lymphocytes enabling the perturbation of
intracellular pathways to dictate cell fate.135
Functional protein delivery has been shown for both covalent attachment as well as
non-covalent delivery. While the polydispersity makes these systems difficult to fully
characterize, they have shown promise in their ability to deliver proteins into cells at a
higher efficiency than their peptide counterparts.136
1.6.2 Nanogels
Nanogels are a type of hydrogel on the order of 10-200 nm and are made of crosslinked soluble polymer chains. They can be modified to encapsulate proteins or to
covalently attach cargo to the surface. The porous nature of hydrogels allows controllable
release kinetics of their cargo based on crosslinking density. During synthesis, no organic
solvents or harsh fabrication techniques are required; polymers that have been most widely
evaluated for the preparation of nanogels include poly(N-isopropylacrylamide) (pNIPAM),
poly(lactic acid) PLA, poly(lactic-co-glycolic acid) (PLGA), poly(caprolactone) (PCL),
polyhydrobuterate, and polypropylene glycol.137,138 Biological materials like dextran,
hyaluronic acid, and chitosan are also used to form nanogels.139 Nanogels, along with the
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other nanocarriers described in this section have been illustrated in Figure 0.9 since many
of them have similar components.

Figure 0.9. Schematic of synthetic nanocarriers.
Active enzymes, such as caspase-3, have been covalently attached to the surface as
well as encapsulated inside polymeric redox sensitive nanogels through disulfide
linkages.140 Further modification with a CPP is required for internalization, and activity of
caspase-3 was restored upon cleavage from the nanogel in the reducing environment of the
cell.
Zhao et al. showed intracellular delivery of caspase-3 encapsulated in redox
responsive nanogels which degrade at lowered pH due to their disulfide containing
crosslinker.
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Single encapsulation of the caspase-3 using the nanogel showed rapid

uptake and trafficking into the cytosol, followed by induced apoptosis. Negative controls
of the nanogel without the caspase-3 and the caspase-3 by itself showed low cytotoxicity
in HeLa, U-87 MG, and MCF-7 cells.
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Crosslinked nanoparticles were synthesized with a pH responsive PDEAEMA
(polydimethyl amino ethyl methacrylate) core and hydrophilic PAEMA (polyazidoethyl
methacrylate) charged shell to deliver OVA into dendritic cells.142 The hydrophobic pH
buffering component facilitated endosomal disruption and cytosolic delivery resulting in
elevated IFN-g production and cross presentation of antigen.
There are several advantages to nanogels as protein carries, including their
biocompatibility due to their high water content, biodegradability, high loading capacity,
and tunable crosslinking densities which allows controlled cargo release.138 Additional
modification can allow stimuli responsive release of cargo including degradation based on
pH, temperature, or an applied electric field.8
1.6.3 Polymeric Micelles
The structure of amphiphilic molecules allows them to accumulate at the boundary
of two non-miscible phases and to function as surfactants. With an increase in
concentration, the free energy begins to rise and at the critical micelle concentration, the
amphiphiles will self-assemble into colloidal sized particles illustrated in Figure 0.9.12
Careful modulation of the relative block lengths and the composition of block copolymer
affects the shape of the overall amphiphile, which affects the packing parameter, giving
rise to micelles or higher order structures such as bilayers. Since assembly is a reversible
process driven by thermodynamics, micelles are categorized as an amphiphilic colloid and
not a solid nanoparticle.143 Proteins can be loaded inside the hydrophobic core of the
micelle for use as a delivery vehicle.
Coué et. al. describe a bioreducible poly(amidoamine) that associate with their
protein cargo through charge reversibility.144 For this system, the charge density of the
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protein of interest was temporarily increased by the modification of the lysine residues to
make them negatively charged carboxylic groups resulting in a strongly anionic surface.
The cationic block copolymers were then associated with the cargo for rapid delivery into
the cytosol. The modifying groups on the lysines are redox sensitive, degrading at a pH of
5.5 releasing the cationic polymer to allow endosomal escape. Functional antibody was
stained for using a secondary antibody after cell fixation. Some activity was lost due to the
initial modification, though presence was detected regardless of modification technique.
Polymer micelles face some inherent problems including low stability in aqueous
environments, low loading capacity, low cellular uptake compared with liposome and
polymersome counterparts, toxicity correlated with an increase in polymer required to
deliver high concentrations of cargo, immunogenicity, and short half lives in biological
environments.12,139
1.6.4 Dendrimers
Dendrimers are a specific type of highly branched, globular macromolecules which
are composed of many arms emanating from a central core.145 As depicted in Figure 0.9,
the inner layers of the dendrimer have a homogeneous structure from every branch point
stemming from the core. In some cases, dendrimers can be end capped with peripheral
functional groups to change surface properties. The iterative nature of dendrimer synthesis
leads to control over density and reactivity of surface functional groups, as well as control
of overall size and molecular structure.146
In general, hydrophobic therapeutic substances are loaded in the non-polar core of
the dendrimer and both positively or negatively charged surface functional groups can be
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used to complex with cargo.137 Only a few examples exist for protein delivery, and those
are limited to cases of low numbers of protein bound per dendrimer.
Bayele et. al. used lysine rich dendrimers to deliver c-Myc monoclonal antibody
into HeLa cells.147 Dendrimers with guanidinium moieties at the end of each branch were
capable of delivering the antibody IgG into HEp-2 cells.148 Cargo with measurable
intracellular function was not used in either of these studies, rather fluorescence was used
to track the uptake. The multivalency of dendrimers make them excellent at interacting
with cell receptors and subsequently being internalized by cells, though there is still much
to be explored in their use to deliver biological cargos.9,149 High cytotoxicity is associated
with dendrimers after incubation for longer time periods.147
1.6.5 Nanocapsules and Polymersomes
Stable self-assembled polymeric shells are similar in morphology to liposomes in
their colloidal nature with an outer layer made from amphiphilic block copolymers.12
Depending on the polymeric component and the nature of the core, two variations exist:
nanocapsules with an oily liquid core and a single outer layer of polymer and
polymersomes with an aqueous core surrounded by a polymer bilayer. The difference
between polymersomes and nanocapsules is depicted in Figure 0.9.
Nanocapsules have found utility in the encapsulation and delivery of hydrophobic
drugs and proteins. Commonly used polymers include PLA, PLGA, and PCL in addition
to poly(ethylene glycol) PEG. The Rotello group has developed a system using
nanoparticles to stabilize nanocapsules for the delivery of biologics into cells.68,150,151 The
synthesis strategy can entrap a variety of cargos including proteins. Caspase-3 and Cas9
have been delivered in tandem with AuNPs using the nanoparticle stabilized emulsion.69,150
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Polymersomes are analogous to liposomes with their ability to encapsulate and
deliver hydrophilic substances but are instead made of block copolymers such as PEG-bPBD (polybutadiene) and PEG-b-PEE (polyethylethylene). While both systems are inert,
neither are biodegradable lending to the creation of PEG-b-PLA and PEG-b-PCL. Another
study using the triblock PEG-PCL-PDEA (polydimethyl amine) polymersomes showed
delivery of FITC labeled lysozyme, cyt-c, OVA, and IgG into HeLa and Raw cells.152
In terms of degradable carriers, anisamide decorated pH sensitive polymersomes
showed efficient loading and delivery of apoptotic granzyme B into H460 lung cells.153
The reducing environment within the cell dissembled the polymersomes allowing release
of granzyme B into the cytosol. Cytosolic delivery induced apoptosis via delivery of
granzyme B when the surface of the polymersomes were functionalized with high levels
of anisamide on the surface. Nanocapsules and polymersomes provide a ripe area of
research for protein delivery because of their ability to encapsulate a variety of cargos and
to be environmentally responsive.
1.6.6 Polyplexes
Polyplexes have been traditionally labeled as a complex between polymers and
DNA, though similar strategies are being applied to proteins.9,154,155 Direct covalent
attachment with polymers such as PEG has been used to improve stability and reduce the
surface charge of proteins. Polymer attachment is easily achieved through well-established
bioconjugation

methods.149

One

of

the

most

commonly

used

polymers

is

polyethyleneimine (PEI) which has been conjugated to the surface of various proteins to
impart positive charge and enhance membrane permeability.156–158 Murata et. al.
functionalized denatured human tumor suppressor p53 with PEI using a reducible disulfide
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bond to deliver the protein into Saos-2 cells. Reduction of the reversibly cationized
complex in the cytosol allowed the p53 to refold into tetramers resulting in nuclear
localization and induction of p53 target genes eventually leading to apoptosis.125 The
system was extended to allow delivery of functional anti-S100C antibodies into HFL-1
cells which could be seen in fluorescence images (Figure 0.10) as long filamentous
structures as they bound to the S100C proteins on the actin filaments.156

Figure 0.10. Confocal microscopy of distribution of FITC-labeled anti-S100C
antibodies localized with actin (A) after delivery with the PEI cationized protein G
into HFL-1 cells (scale bar 50 µm). Delivery of a non-specific protein with PEI-protein
G resulted in unpatterned delivery (B). Lower images are differential interference
contrast images corresponding to the upper panels. Arrowheads indicate filamentous
structures. Image adapted from Kitazoe et. al.156
In another case, cytosolic delivery of MoAb 64.1 was demonstrated in Jurkat T
cells using polypropylacrylic acid.159 The antibody was conjugated to streptavidin which
readily complexed with the biotinylated polymer allowing for release into the cytosol as
determined by quantitative western blot.
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1.6.7 Insight
Polymer nanocarrier systems are one of the fastest growing transduction methods
due to facile synthesis and high uptake of detectable bioactive cargo. Synthetic carriers tout
enhanced cargo stability in addition to permeability, though many studies do not look at
the long term effects of the synthetic systems within cells. Additionally, there has been
very few systematic comparisons between polymer systems probing how formulation and
preparation effects protein delievery.160 Expansion into structure activity relationships, as
well as understanding how the protein cargos interact with their carriers is critical to
improving polymer design for improved uptake and protein function.

1.7

Perspective
The intracellular delivery of functional proteins is an important task as it opens the

doors to understanding and manipulating intracellular pathways with low toxicity and
minimal interruption in normal cellular processes. Effective and safe delivery systems
facilitate progress in multiple fields from cell bases therapies to molecular biology. Current
demand for these delivery vehicles exceeds supply, especially in fields that are interested
in treatment of primary and patient derived cells such as immune cells, neurons, and stem
cells.
One major challenge that the field of protein delivery currently faces is the lack of
standard experimental conditions to compare across all protein delivery methods. Many
publications (not included in this review) only deliver fluorescently labeled cargos, which
have no other detectable bioactivity, and rarely do the authors follow up with proteins that
do show a bioactive readout. Model proteins that exhibit function either in the cytosol or
nucleus easily demonstrate endosomal escape and the stabilizing capacities of the carriers.
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Additionally, researchers have tendencies and preferences for certain cell lines which limits
the diversity of cells studied and makes comparisons between methods even more
challenging. Many of the reported cell lines, like HeLas, are known to be relatively easy to
transfect and transduce, providing little barrier and less proof of concept. Here, the authors
would like to encourage the field to begin to choose proteins that have a functional readout
within the cells they are delivered into, and to deliver into cell lines or primary cells that
have practical application such as immune cells or neurons.
An important, yet unanswered question that protein delivery faces is how much
protein is required to have a biological response. Without quantification, or understanding
of how concentration effects an intracellular pathway, it remains elusive whether one
protein or many are needed to register a biological readout. Therefore, higher number of
delivered proteins is not necessarily as important for functional protein delivery. Direct
structure activity relationships would help elucidate this problem, furthering the
development of more effective protein delivery.
The future of protein delivery is dependent on interdisciplinary research to facilitate
the interface of biology and technology. Advances in delivering proteins across the
membrane will lead to new challenges. Solving these next generation problems may hinge
on our ability to understand current delivery mechanisms and implement analytical
approaches necessary to characterize cellular response. Despite the barriers that remain,
next generation technologies will translate beyond academic endeavors into personalized
diagnostics and therapeutics.

34

1.8

Thesis Overview
The aim of the following thesis was to characterize, optimize, and utilize PTDMs

for functional protein delivery. The PTDMs reported here provide a well-controlled
platform to vary molecular composition for structure activity relationship studies to further
our understanding of PTDs, their non-covalent association with cargo, and their cellular
internalization pathways. Specifically, several polyoxanorbornene-based synthetic mimics
were synthesized using ring-opening metathesis polymerization (ROMP) due to its
relatively precise control over molecular weight and polydispersities. The living nature of
ROMP allows for the formation of advanced architectures such as block copolymers which
can be used to investigate the relationship between structure and internalization activity.
Elucidating the predominant cellular entry mechanism for protein transduction
domains (PTDs) and their synthetic mimics (PTDMs) is a complicated problem that
continues to be a significant source of debate in the literature. In Chapter 2, several
guanidine rich homopolymers, along with an amphiphilic block copolymer were used to
investigate the relationship between structure and internalization activity in HeLa cells,
both alone and non-covalently complexed with EGFP by flow cytometry and confocal
imaging. The findings indicate that while changing the amount of positive charge on our
PTDMs does not seem to affect the endosomal uptake, the presence of hydrophobicity
appears to be a critical factor for the polymers to enter cells either alone, or with associated
cargo.
In Chapter 3, a series of polyoxanorbornene-based synthetic mimics, inspired by
PTDs, with varying cationic and hydrophobic densities, and the nature of the hydrophobic
chain and degree of polymerizations were investigated in vitro to determine their ability to
non-covalently transport enhanced green fluorescent protein into HeLa cells, Jurkat T cells,
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and hTERT mesenchymal stem cells. Polymers with high charge density lead to efficient
protein delivery. Similarly, the polymers with the highest hydrophobic content and density
proved to be the most efficient at internalization. The observed improvements with
increased hydrophobic length and content were consistent across all three cell types,
suggesting that these architectural relationships are not cell type specific. These results
provide important design parameters for intracellular delivery of proteins and produced a
candidate polymer for further investigation.
Delivery of a model protein, GFP, into several human cell types using the lead
PTDM compared with four commercially available counterparts is explored in Chapter 4.
This comparison reveals that while many of the protein delivery vehicles within the class
of amphiphilic polymers are able to deliver into cells in serum free conditions, their
delivery is severely hampered in the presence of serum. In contrast, the PTDM reported
here is capable of high protein delivery into all tested cell types within 4 hours in the
presence of complete media.
Lastly, to show functional protein delivery, in Chapter 5 we investigated the ability
of these PTDMs to deliver a peptide into whole blood and subsequent stimulation of a
directed immune response toward the specific peptide sequence. We have detected peptide
delivery to over 90% of CD14+ monocytes in less than 15 minutes with nominal cytokine
response and high cell viability. The co-delivery of an agonist to promote a specific
immune response against the peptide in vitro allowed us to modulate monocyte
differentiation and presentation of the specific peptide in association with MHC class I
molecules. The ability to have a specific response with the cargo of interest verifies
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cytosolic delivery using the PTDMs and provides valuable insight into their use to affect
immune cells.
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CHAPTER 2
RELATING STRUCTURE AND INTERNALIZATION FOR ROMP-BASED
PROTEIN MIMICS
2.1. Introduction
Over the past decade, intracellular targeting has become an emerging area of
research in drug delivery, diagnostics, and chemical biology. However, cell membranes are
impermeable to most macromolecules and small molecules. One exception seems to be a
class of cell-penetrating peptides (CPPs) known as protein transduction domains (PTDs)
and their synthetic mimics (PTDMs). Intracellular delivery using PTDs remains a
promising method for introducing exogenous macromolecules into cells.161,162
The Tat (transactivator of transcription) protein of the human immunodeficiency
virus type 1 (HIV-1), discovered in 1988, was the first identified PTD.163,164 Later, it was
determined that an eleven amino acid residue sequence (YGRKKRRQRRR), rich in basic
amino acids, was required for translocation of Tat through the plasma membrane.165 In the
last two decades, over 100 CPP sequences have been published and this number continues
to expand as more is learned about these molecules.166 These CPPs are usually small,
cationic peptides, some of which contain a hydrophobic component. Their main feature is
their ability to cross cell membranes either on their own or conjugated to a range of
biomolecules, such as peptides, proteins, liposomes, and nanoparticles. This is possible at
micro-molar concentrations without causing significant membrane damage.58 Synthetic
CPPs deviate from naturally occurring protein sequences and are either designed to mimic
their structures and compositions or to produce amphipathic a-helical structures. Examples
are the model amphipathic peptide (MAP) and oligoarginine sequences, such as R8. These
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synthetic CPPs have also been covalently attached to various macromolecules and their
internalization has been studied.167,168
Intracellular delivery of large molecules, including macromolecules and liposomes,
often involves the uptake of PTD(M) complexes by endocytosis.169 Arginine-rich PTDMs
have been proposed to induce macropinocytosis, which in turn leads to accelerated
internalization of cell surface adsorbed PTDMs and PTDM-cargo complexes.170–172 Since
macropinocytosis is considered a non-specific fluid phase endocytosis pathway, its
induction should facilitate indiscriminate uptake.173 The endosomal route usually finishes
with the acidic and proteolytic degradation of the lysosomal content, thus preventing the
delivered cargo from reaching its cytosolic targets.174 The release of biologically active
cargo from endosomes is a necessary step and is a major limitation for this type of uptake.58
A second mode of uptake is direct translocation, an energy-independent penetration
pathway in which a transient destabilization occurs in the membrane, followed by the rapid
intracellular localization of the peptide.175–177 For drug delivery purposes, it is preferred
that molecules enter cells by direct translocation, as this pathway does not incur endosomal
entrapment. Changes in hydrophobicity have been implicated as the driving factor for
arginine-rich molecules to cross cell membranes through direct translocation.178
Additionally, cell surface concentrations of arginine-rich PTDMs may also play a role in
peptide entry into cells.179 Some peptides exceeding a threshold concentration have been
observed to directly penetrate the membrane, while at lower concentrations uptake is
primarily by endocytosis.177,180,181
A change in membrane curvature is required for both endocytosis and direct
penetration, which can be facilitated by CPP–membrane interactions.182 Decoupling
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endocytosis from direct penetration remains largely unsolved. The use of endocytosis
inhibitors may alter other cellular processes, making deconvolution of the treatments
difficult.183 Cooling cells to 4 ˚C provides another challenge in that cooler temperatures
affect the membrane fluidity making it more rigid and therefore more permeable to larger
molecules.184
While many CPPs and their mimics show high membrane permeability and
efficient cargo delivery, the mechanisms by which PTDMs and PTDM-cargo complexes
traverse cell membranes are not completely understood and are highly debated in the
literature.183 The methods by which arginine-rich PTDs are internalized depend on the
physiochemical properties of the PTDs, the cargo molecules, and cell type, as well as a
variety of other parameters. Therefore, it is not surprising that the predominant
internalization mechanism may deviate depending on the attached cargo. Understanding
this cellular uptake mechanism of CPPs under physiological conditions is important for the
development of appropriate strategies for therapeutic applications both in vitro and in vivo.
Since several routes may exist simultaneously, it is important to correlate the uptake
pathway with the biological response associated with a specific cargo e.g. if the target of
the cargo is cytosolic or endosomal. These parameters will enable the design of materials
to target specific routes of internalization.
Creating polymeric scaffolds with CPP-like internalization and cargo delivery
properties has recently emerged as a new research direction.114–116 Polymers allow for the
use of different, easily tailored chemistries and architectures for investigating structure
activity relationships, while tuning for efficient cargo delivery. Using ring-opening
metathesis polymerization (ROMP), which is functional group tolerant, well-controlled,
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and versatile, a highly efficient set of synthetic PTDMs has been developed.114,115,185–190
These designs, based on polyarginine, are guanidinium-rich and allow for non-covalent
internalization of various biological cargos.187,188,191 The ability to easily include diverse
functional groups allows us to probe architecture, molecular composition, and molecular
weight in a controlled manner, mimicking peptide synthesis.114,191
Polymeric mimics offer a controlled way to explore the effects of structure and
macromolecular composition on internalization efficiency. Using R8 as inspiration and a
benchmark, a set of four homopolymers and one block copolymer (Figure 0.1) were chosen
to investigate the impact of polymer structure and backbone on internalization efficiency
in HeLa cells.
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Figure 0.1. Polymers of interest: R8 inspired the design of dG5 (n=5), dG10 (n=10),
MeG10, PGON20, and MePh10-b-dG5.
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Determining the parameters that dictate the predominant method of internalization
is crucial to the understanding and optimization of CPPs and their mimics. In this work,
we use the delivery of cargo by synthetic PTDMs as a handle for elucidating the
intracellular pathways through which these molecules enter. More specifically, HeLa cells
were treated with the chosen PTDMs, either with a FITC label or associated with
fluorescent protein, allowing for confocal laser scanning microscopy (CLSM) and flow
cytometry (FCM) analysis. Imaging explicates the predominant mode of uptake as
endosomal uptake and allows us to address some of the more difficult questions regarding
polymer-cell interactions, while flow cytometry generates quantitative results (on a much
larger number of cells) that can be used to verify trends seen with imaging. From these
results, we determined that concentration and polymer architecture have little effect on the
mode of translocation into the cell, but rather play a more important role in how much
cargo they are able to deliver.
2.2. Materials and Methods
2.2.1. Materials
Chemicals were obtained as reagent grade from Aldrich, Fluka, or Acros and used
as received. 3rd generation Grubbs catalyst (Dichloro-di(3-bromopyridino)-N,N’Dimesitylenoimidazolino-Ru=CHPh; G3) was synthesized as described previously by
Grubbs et al. (1). The ACS reagent grade solvents, ethyl acetate, tetrahydrofuran (THF),
N,N-dimethylformamide (DMF), and pentane, were purchased from Fisher Scientific and
used as received. Dichloromethane (DCM) (ACS reagent grade, Fisher Scientific) was
distilled from CaH2 under nitrogen. Deuterated solvents for NMR were purchased from
Cambridge Isotope Laboratories. Spectra/Por® Biotech cellulose ester dialysis membranes
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with the molecular weight cut off of 100-500 were purchased from Spectrum Medical
Industries. Media and supplements for cell culture were purchased from Lonza.
2.2.2. Instrumentation
1

H spectra were recorded at 300 MHz, using a Bruker DPX-300 NMR

spectrometer. Chemical shifts (δ) are reported in ppm and coupling constants (J) in Hz.
The abbreviations for splitting patterns are: s, singlet; d, doublet; dd, doublet of doublets;
t, triplet; q, quartet; m, multiplet; br, broad. Gel permeation chromatography was measured
on an Agilent 1260 series GPC setup with a PL Gel 5 µm guard column, two 5 µm
analytical Mixed-C columns, and a 5 µm analytical Mixed-D column (Agilent), incubated
at 40 °C, with RI detector. THF was used as the eluent at a flow rate of 1.0 mL/min.
Polystyrene standards were used for the calibration and toluene was used as flow marker.
Flow cytometry was performed on an LSRII flow cytometer and analyzed using the
acquisition software FACSDiva™ (BD®). Analysis of flow cytometry data was performed
using FlowJo™ (Tree Star®) software. Images were taken using a FV1000 Olympus®
IX81 confocal laser scanning microscope (CLSM) at both 40 and 60X.
2.2.3. PTDM Synthesis
2.2.3.1.

Monomer Synthesis

Monomers and PTDMs were synthesized according to established literature
procedures.185,187,189 The diester monomers were synthesized using the procedure
introduced by Lienkamp et al.192 In general, the Diels-Alder adduct 1 was obtained by the
reaction of maleic anhydride with furan in toluene.
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product was purified via column chromatography with silica gel using DCM/ethyl acetate
(8:2) as eluent. Vacuum evaporation of the solvent yielded the pure product with a yield of
~80%.
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3 (dG): 1H NMR (300 MHz, CD3CN): δ 11.54 (s, 2H), 8.35 (s, 2H), 6.44 (s, 2H), 5.17 (s,
2H), 4.33 – 3.97 (m, 4H), 3.72 – 3.41 (m, 4H), 2.82 (s, 2H), 1.48 (s, 9H), 1.42 (s, 9H); 13C
NMR (75 MHz, CD3CN): δ 172.43, 164.51, 157.35, 153.72, 137.56, 84.05, 81.41, 79.50,
63.72, 47.49, 40.21, 28.38, 28.09; HR-MS (FAB) m/z [M+H]+: 755.3827 (calc.), 755.3824
(found).
Compound 1, 1.5 equivalents of methanol, and 10 mol% DMAP were dissolved in
dry DCM and the reaction was stirred for 3 days at room temperature. Solvent was
evaporated and the product was crystalized in a 1:1 mixture of chloroform:hexanes with a
yield of ~60%.The product was dissolved in dry DCM along with 1.5 equivalents of 1,2-
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Di-Boc-2-ethyl guanidine, and 10 mol% DMAP and the solution was cooled to 0˚C. 1
equivalent of EDC was added and the reaction was stirred overnight at room temperature.
The product was washed with brine, evaporated down, and purified using column
chromatography with silica gel 9:1 DCM:ethyl acetate. The yield was ~70%.
4 (MeG): 1H NMR (300 MHz, CD3CN): δ 11.50 (s, 1H), 8.55 (s, 1H), 6.46 (s, 2H), 5.3 (d,
2H), 4.25 (m, 2H), 3.72(m, 5H), 2.84 (s, 2H), 1.49 (s, 18H). 13C NMR (75 MHz, CD3CN):
δ 171.7, 171.5, 163.4, 156.3, 153.1, 136.6, 83.2, 80.7, 80.6, 79.4, 63.5, 52.4, 47.1, 46.4,
39.4, 28.3, 28.1; HR-MS (FAB) m/z [M+H]+: 483.22 (calc.), 484.23 (found).
Compound 1, 1.5 equivalents of benzyl alcohol, and 10 mol% DMAP were
dissolved in dry DCM and the reaction was stirred for 3 days at room temperature. The
product was precipitated out of DCM and was filtered and vacuum evaporated to yield the
pure product with a yield of ~70%. The product was dissolved in 1:1 mixture of DCM:THF
along with 2 equivalents of methanol and 10% DMAP and the solution was cooled down
to 0˚C in an ice bath. 1 equivalent of EDC was added and the solution was stirred over
night at room temperature. Solvent was evaporated off and the reaction mixture was
dissolved in minimal DCM. Purification of monomer MePh was performed via column
chromatography with silica gel using DCM:ethyl acetate (8:2) as eluent. Vacuum
evaporation of the solvent yielded the pure product with a yield of ~80%.
(MePh): 1H NMR (300 MHz, CD3CN): δ 7.34 (d, J = 3.0 Hz, 10H), 6.44 (s, 2H), 5.16 (s,
2H), 4.97 (dd, J = 45.5, 12.4 Hz, 4H), 2.87 (s, 2H); 13C NMR (75 MHz, CD3CN): δ 172.37,
137.52, 137.03, 129.41, 129.14, 129.06, 81.30, 67.26, 47.58; HR-MS (FAB) m/z [M+H]+:
365.1389 (calc.), 365.1398 (found).
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The imide monomer was synthesized using a procedure previously developed by
Gabriel et al. 2 In general, the Diels-alder adduct was obtained by the reaction of maleimide
with furan in ethyl acetate at 90˚C for 3 hours. The product, 1,2-Di-Boc-2-ethyl guanidine,
and triphenylphosphine were dissolved in THF and cooled to 0˚C. 1 equivalent of
diisopropyl azodicarboxylate (DIAD) was added dropwise and reaction was stirred for 24
hours at room temperature. Solvent was removed by evaporation and recrystallized in
methanol twice to yield 40% of the GON monomer.
5 (GON): 1H NMR (300 MHz, CD3CN): δ 11.44 (s, 1H), 8.35 (t, J = 6.0 Hz, 1H), 6.56 (s,
2H), 5.10 (s, 2H), 3.52 (m, 2H), 3.43 (m, 2H), 2.85 (s, 2H), 1.47 (s, 9H), 1.36 (s, 9H); 13C
NMR (75 MHz, CD3CN): δ 176.3, 156.6, 153.0, 136.5, 83.3, 80.9, 47.6, 39.0, 38.4, 28.3,
28.1.
2.2.3.2.

Activated Ester Synthesis

Activated ester was synthesized according to the procedure introduced by Madkour
et al. Briefly, compound B was synthesized as described in the literature. 3 Compound A,
pentafluorophenol, and DMAP were dissolved in 50 mL dry DCM under nitrogen. The
resulting solution was then cooled to 0˚C, and EDC was added to the mixture in portions.
The reaction mixture was then allowed to warm to room temperature and stirred for another
12 hours. The mixture was then washed with 10% KHSO4 solution, saturated NaHCO3
solution, and brine. The resulting DCM solution was dried using anhydrous Na2SO4,
filtered, and the solvent was evaporated. The resulting residue was purified by filtration
through a neutral alumina plug using DCM as the eluent.
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H-NMR (300 MHz, CDCl3): δ 5.77 (m, 2H), 4.75 (d, J = 5.6 Hz, 4H), 3.05 (t, J = 6.2 Hz,

4 H), 2.95 (t, J = 6.2 Hz, 4H); 13C-NMR (75 MHz, CDCl3): δ 171.1 (C=O-O allylic), 168.4
(C=O-O-C6F5), 142.9, 141.7, 139.5,137.8 & 136.1 (m, F5C6), (CH2-C=C), 28.7 & 28.3
(CH2-CH2).
2.2.3.3.

Polymer Synthesis

Example of reaction conditions for homopolymer synthesis: Monomer (MeG or
dG) and G3 catalyst were dissolved in dry DCM in respective schlenk flasks, purged with
nitrogen and subjected to three freeze-pump-thaw cycles. The monomer solution was
added into the catalyst solution via syringe all at once. The brown solution was stirred for
2 hours (30 minutes for the PGON20) at room temperature. The reaction was terminated
with 1 mL of ethyl vinyl ether and stirred for 30 minutes. DCM was evaporated and the
product dissolved in minimal DCM to be loaded on a short silica gel column (7 cm length,
3 cm diameter). The unreacted end-group and any side products were washed from the
column with DCM, while polymer remained on the column and was recovered with ethyl
acetate. Ethyl acetate was evaporated to yield the pure product.
MeG10: 1H-NMR (300 MHz, CDCl3): d 11.55 (1H, br), 8.42 (1H, br), 7.39 (0.5H, br), 5.88
(trans) and 5.63 (cis) (2H total, br), 5.02 (cis) and 4.70 (trans) (2H total, br), 4.14 (2H, br),
3.65 (5H, br), 3.17 (2H, br), 1.49 (18H, s).
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dG5: 1H-NMR (300 MHz, CDCl3): d 11.56 (2H, br), 8.41 (2H, br), 7.35 (1H, br), 5.93
(trans) and 5.66 (cis) (2H total, br), 5.07 (cis) and 4.69 (trans) (2H total, br), 4.17 (4H, br),
3.59 (4H, br), 3.21 (2H, br), 1.53 (18H, s), 1.44 (18H, s).
dG10: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.34 (0.5H, br), 5.93
(trans) and 5.65 (cis) (2H total, br), 5.10 (cis) and 4.69 (trans) (2H total, br), 4.20 (4H, br),
3.58 (4H, br), 3.19 (2H, br), 1.52 (18H, s), 1.44 (18H, s).
PGON20: 1H-NMR (300 MHz, CDCl3): d 11.57 (1H, br), 8.39 (1H, br), 7.34 (0.25H, br),
6.00 (trans) and 5.81 (cis) (2H total, br), 5.00 (cis) and 4.43 (trans) (2H total, br), 3.60 (2H,
br), 3.33 (2H, br), 2.09 (2H, br), 1.38 (18H, s).

Reaction conditions for block copolymer synthesis: Monomer dG, monomer
MePh, and G3 catalyst were dissolved in dry DCM in respective schlenk flasks, purged
with nitrogen, and subjected to three freeze-pump-thaw cycles. Monomer dG solution was
added into the catalyst solution via syringe all at one time. The brown solution was stirred
for 30 minutes at room temperature before monomer MePh was introduced. After stirring
for an additional 2 hours, the reaction was terminated with 1 mL of ethyl vinyl ether and
stirred for 30 minutes. DCM was evaporated and the product was dissolved in minimal
DCM and loaded on a short silica gel column (7 cm length, 3 cm diameter). The unreacted
end-group and any side products were washed from the column with DCM, while polymer
remained on the column and was recovered with ethyl acetate. Ethyl acetate was
evaporated to yield the pure product.
MePh10-b-dG5: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.37 (6H,
br), 5.80 (trans) and 5.61 (cis) (4H total, br), 5.08 (2H, br), 5.00 (cis) and 4.77 (trans) (4H
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total, br), 4.66 (2H, br), 4.17 (4H, br), 3.64 (4H, br), 3.49 (3H, br), 3.17 (4H, br), 1.46 (18H,
s), 1.41 (18H, s).

Polymers were synthesized in a similar manner to that listed above but terminated
with 20 mole equivalents activated ester (compound B) dissolved in a minimal amount of
DCM and stirred overnight. DCM was evaporated and the product dissolved in minimal
DCM to be loaded on a short silica gel column (7 cm length, 3 cm diameter). The unreacted
end-group and any side products were washed from the column with DCM, while polymer
remained on the column and was recovered with ethyl acetate. Ethyl acetate was
evaporated to yield the pure product.

MeG10: 1H-NMR (300 MHz, CDCl3): d 11.55 (1H, br), 8.42 (1H, br), 7.39 (0.5H, br), 5.88
(trans) and 5.63 (cis) (2H total, br), 5.02 (cis) and 4.70 (trans) (2H total, br), 4.14 (2H, br),
3.65 (5H, br), 3.17 (2H, br), 3.01 (cis) and 2.77 (trans) (0.4H total, br), 1.49 (18H, s).
dG5: 1H-NMR (300 MHz, CDCl3): d 11.56 (2H, br), 8.41 (2H, br), 7.35 (1H, br), 5.93
(trans) and 5.66 (cis) (2H total, br), 5.07 (cis) and 4.69 (trans) (2H total, br), 4.17 (4H, br),
3.59 (4H, br), 3.21 (2H, br), 3.02 (cis) and 2.77 (trans) (0.8H total, br), 1.53 (18H, s), 1.44
(18H, s).
dG10: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.34 (0.5H, br), 5.93
(trans) and 5.65 (cis) (2H total, br), 5.10 (cis) and 4.69 (trans) (2H total, br), 4.20 (4H, br),
3.58 (4H, br), 3.19 (2H, br), 3.01 (cis) and 2.77 (trans) (0.4H total, br), 1.52 (18H, s), 1.44
(18H, s).
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PGON20: 1H-NMR (300 MHz, CDCl3): d 11.57 (1H, br), 8.39 (1H, br), 7.34 (0.25H, br),
6.00 (trans) and 5.81 (cis) (2H total, br), 5.00 (cis) and 4.43 (trans) (2H total, br), 3.60 (2H,
br), 3.33 (2H, br), 3.02 (cis) and 2.79 (trans) (0.2H total, br), 2.09 (2H, br), 1.38 (18H, s).
MePh10-b-dG5: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.37 (6H,
br), 5.80 (trans) and 5.61 (cis) (4H total, br), 5.08 (2H, br), 5.00 (cis) and 4.77 (trans) (4H
total, br), 4.66 (2H, br), 4.17 (4H, br), 3.64 (4H, br), 3.49 (3H, br), 3.17 (4H, br), 3.01 (cis)
and 2.77 (trans) (0.3H total, br), 1.46 (18H, s), 1.41 (18H, s).
100 mg end-functionalized polymer was dissolved in 1 mL amine-free DMF. 2
mole equivalents of fluorescein-5-thiosemicarbazide were added. The reaction was
allowed to stir at room temperature for three days. The solvent was evaporated, and the
reaction product was purified by column chromatography using ethyl acetate.
MeG10: 1H-NMR (300 MHz, CDCl3): d 11.55 (1H, br), 8.42 (1H, br), 7.39 (0.5H, br), 5.88
(trans) and 5.63 (cis) (2H total, br), 5.02 (cis) and 4.70 (trans) (2H total, br), 4.14 (2H, br),
3.65 (5H, br), 3.17 (2H, br), 3.01 (cis) and 2.77 (trans) (0.4H total, br), 1.49 (18H, s).
dG5: 1H-NMR (300 MHz, CDCl3): d 11.56 (2H, br), 8.41 (2H, br), 7.35 (1H, br), 5.93
(trans) and 5.66 (cis) (2H total, br), 5.07 (cis) and 4.69 (trans) (2H total, br), 4.17 (4H, br),
3.59 (4H, br), 3.21 (2H, br), 3.02 (cis) and 2.77 (trans) (0.8H total, br), 1.53 (18H, s), 1.44
(18H, s).
dG10: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.34 (0.5H, br), 5.93
(trans) and 5.65 (cis) (2H total, br), 5.10 (cis) and 4.69 (trans) (2H total, br), 4.20 (4H, br),
3.58 (4H, br), 3.19 (2H, br), 3.01 (cis) and 2.77 (trans) (0.4H total, br), 1.52 (18H, s), 1.44
(18H, s).
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PGON20: 1H-NMR (300 MHz, CDCl3): d 11.57 (1H, br), 8.39 (1H, br), 7.34 (0.25H, br),
6.00 (trans) and 5.81 (cis) (2H total, br), 5.00 (cis) and 4.43 (trans) (2H total, br), 3.60 (2H,
br), 3.33 (2H, br), 3.02 (cis) and 2.79 (trans) (0.2H total, br), 2.09 (2H, br), 1.38 (18H, s).
MePh10-b-dG5: 1H-NMR (300 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.37 (6H,
br), 5.80 (trans) and 5.61 (cis) (4H total, br), 5.08 (2H, br), 5.00 (cis) and 4.77 (trans) (4H
total, br), 4.66 (2H, br), 4.17 (4H, br), 3.64 (4H, br), 3.49 (3H, br), 3.17 (4H, br), 3.01 (cis)
and 2.77 (trans) (0.3H total, br), 1.46 (18H, s), 1.41 (18H, s).
2.2.4. Deprotection
The polymers were dissolved in 2 mL DCM and 2 mL trifluoroacetic acid (TFA)
for deprotection. After stirring overnight, the excess acid was removed by azeotropic
distillation with methanol. After complete evaporation of the acid, samples were dissolved
in water/methanol mixture and dialyzed against RO water until the conductivity of water
was ~0.1µS. The deprotected copolymer was recovered by lyophilization. Final
deprotected polymer was stored at -20 ºC.
2.2.5. Internalization of FITC-Labeled Polymers
HeLa cells were seeded at 1x104 cells/ 2 mL of a-MEM with 10% FBS on 35 mm
glass bottom plates 48 hours prior to treatment and cultured at 37˚C and 5% CO2. FITCPTDMs were diluted 1:10 in PBS and then to a final concentration of 5, 10, and 20 µM in
a-MEM with 10% FBS. Cells were washed with warm, fresh, complete media and 200 µL
of PTDM solution was applied on top of the glass bottom. Cells were incubated for one
hour and then washed three times with cold media to remove excess PTDM and to slow
cellular function. Cells were covered in 1 mL of cold media and imaged at 60X with
confocal laser scanning microscope (CLSM).
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To investigate co-localization with lysosomes, cells were treated with 5 µM FITCPTDM and 20 nM lysotracker red for 1 hour. Samples were analyzed in a similar manner
to the internalization experiments using both red and green lasers on the CLSM.
Correlation between the location of the lysotracker and the FITC-PTDM was determined
by Pearson’s co-localization coefficient (PCC) using Autoquant® software.
2.2.6. EGFP Delivery
HeLa cells were seeded at 1x106 cells/ 2 mL of a-MEM with 10% FBS on 35 mm
glass bottom plates and 1x105 cells/ 1 mL on 12-well plates 48 hours prior to treatment and
cultured at 37˚C and 5% CO2. Polymer was complexed with 2 µg of EGFP using previously
reported methods at a ratio of 20:1 PTDM to protein (unpublished). Cells were treated for
four hours with the polymer/protein complexes in a total volume of 1 mL a-MEM with
10% FBS. Before imaging, cells were washed three times with cold media and covered in
1 mL fresh, cold a-MEM with 10% FBS. Cells were imaged using CLSM at 60X. To
prepare for flow cytometry (FCM), the cells were lifted using trypsin and washed three
times with a 20 U/mL heparin solution before being suspended in PBS with 0.2 wt% FBS.
To determine if the 30 minute incubation period was required for optimal uptake,
cells were treated with PTDMs not incubated with protein at the same concentration.
PTDMs and protein were diluted as stated above and added drop-wise without mixing into
the media. Uptake was analyzed by flow cytometry to determine the percentage of cells
that internalized the polymer, as well as the median fluorescence intensity (MFI) of the
cells. Cell viability was determined using 7-aminoactinomycin D (7-AAD) staining.
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2.3. Results and Discussion
2.3.1. Polymer Design and Synthesis
In this study, PTDMs were designed to resemble R8 (Figure 0.1), with MeG10
containing one guanidinium group per repeat unit, yielding about 10 positive charges per
polymer. The diguanidine (dG) series (dG5 and dG10) was designed to create a higher
density of guanidinium groups to better mimic the distribution of charge along the peptide
backbone. dG5, with about 10 positive charges, correlates to R8 in that it has approximately
the same number of guanidinium groups, but only half the number of repeat units, while
dG10 has approximately the same number of repeat units as R8, but has twice as many
guanidinium moieties, or about 20 positive charges. A second ROMP backbone, the imidebased poly-guanidinium oxanorbornene (PGON), was added to the series because of its
high membrane activity with lipid vesicles.189 Since PGON20 only contains one
guanidinium group per repeat unit, a length of 20 was chosen for comparison to dG10,
resulting in about 20 positive charges along the length of the polymer. Lastly, a block
copolymer with 10 hydrophobic and 5 diguanidinium monomers (MePh10-b-dG5) was
included because of its efficient non-covalent protein delivery into Jurkat T Cells
(unpublished), predominantly due to the added hydrophobicity that has been shown to be
required for efficient protein delivery. Added hydrophobicity, which has been predicted to
increase saddle splay curvature, combined with lipid head-group coordination by
guanidinium groups, promotes membrane permeation.182 These polymers were all
synthesized with and without covalently attached FITC labels.
2.3.2. Internalization of FITC-Labeled Polymers
HeLa cells were treated with FITC-PTDMs for 1 hour and imaged using a CLSM,
as shown in Figure 0.2A, and also analyzed using flow cytometry (Figure 0.2B and C).
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Images revealed that dG5 and MeG10 exhibited low cell entry. MeG10 appeared to
aggregate extensively and was dropped from further studies. This aggregation could be due
to the overall charge density being too low, with one charge per monomer, allowing the
PTDMs to have a greater self-affinity than for the solution or cell membranes. Both
homopolymers with 20 guanidinium units (PGON20 and dG10) demonstrated efficient
internalization, particularly PGON20. This is unsurprising, as previous reports have shown
that it is highly membrane active in biophysical assays compared to other homopolymers
produced in this group.185 The block copolymer PTDM also showed punctate
internalization throughout the cell with high efficiency for all imaged cells.
The median fluorescence intensities (MFIs), shown in Figure 0.2B, corroborate the
confocal images. An artificially high MFI is expected from MeG10, since large aggregates
were seen in and on cells in the confocal images. dG10 and PGON20 showed high
membrane activity (see Figure 0.2) and consequently result in a 3 to 4 fold higher MFI than
MePh10-b-dG5. We speculate that efficient internalization with the dye requires a
combination of a critical hydrophobic component and charge content that is not met with
dG5. Along this line of thought, the internalization of PGON20 could be attributed to its
increased length. Although MePh10-b-dG5 resulted in a low MFI, the punctate fluorescence
was prevalent in all imaged cells, and more than 95% of the cell population was fluorescent.
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Figure 0.2. Internalization of FITC-labeled PTDMs into HeLa cells. Cells were
treated with 5 µM PTDM for 1 hour and imaged with a CLSM (A) and assessed for
fluorescence internalization using a flow cytometer for both MFI (B) and a positive
shift in intensity from the blank (grey) in FCM histograms (C). Polymer colors in (B)
correspond to their respective shifts in (C).
While punctate fluorescence is easily visible, the location and type of endosomal
compartments was still in question. To determine if the PTDMs were trapped in endosomes
and if those endosomes were bound for degradation, co-localization with lysotracker was
investigated.
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2.3.3. Co-localization with Lysosomes
To compare the location of internalized PTDMs with late endosomal
compartments, cells were treated with lysotracker red during the treatment with FITCPTDMs (Figure 0.3). FITC-PTDMs (green) trapped in late endosomes should co-localize

PGON20
MePh10-b-dG5
R8

dG10

dG5

with the lysotracker red, indicated by yellow.

Figure 0.3. Internalization of FITC-PTDMs (green) in the presence of lysotracker
(red) in HeLa cells. Cells were treated with 5 µM FITC-labeled polymer and
lysotracker red for one hour and imaged using a CLSM.
While the diester homopolymers (dG5 and dG10) proved less successful at
internalization, R8, PGON20, and MePh10-b-dG5 showed robust internalization in punctate
structures. Some of the MePh10-b-dG5 appears to overlap with the lysotracker red,
suggesting that endosomal entrapment is involved in internalization. The enlargement of
MePh10-b-dG5 with lysotracker red is overlapped (yellow), but mutual exclusion of the
polymer (green) from the late endosomes (red) also exists. The Pearson’s Correlation
Coefficient (PCC) for the homopolymer PTDMs and R8 was approximately 0.3 for all
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samples, suggesting little to no correlation between the lysotracker and the polymer, while
MePh10-b-dG5 had a PCC of 0.8, suggesting high co-localization with the late endosomes.
In other words, the hydrophobic PTDM was able to internalize in late endosomes but was
not exclusively located there. This suggests that while some PTDM is permanently trapped
in endosomes, it is not necessarily all destined for degradation. Additionally, escape from
endosomal compartments cannot be dismissed. Longer time periods of this study with a
more photo stable dye would allow for further investigation on the kinetics of our polymers
within cells but was not the focus of this study.
2.3.4. Concentration Dependence
Since the mechanism of uptake can be dependent on the experimental conditions,
an increase in concentration of MePh10-b-dG5 and R8 was used to investigate the effect of
concentration on the predominant mode of internalization. Increasing the concentration
appeared to increase the amount of R8 and MePh10-b-dG5 that entered the cell, although
with increasing cytotoxicity (Figure 0.4A). Confocal images showed that at higher
concentrations of both PTDMs, cells began to bleb and appeared unhealthy. More
aggregated punctate fluorescence suggests compromise of the cellular membrane. The
increase in fluorescence intensity and decrease in viability (using 7-AAD) with increasing
concentration was quantified using flow cytometry. As shown in Figure 0.4, R8 decreases
to approximately 20% viability, while MePh10-b-dG5 showed lower induced apoptosis
even at higher concentrations of PTDMs despite considerable blebbing apparent in the
CLSM images. There was no change in mechanism observed, as fluorescence remained
punctate in all images, even after four hours. Although persistent punctate structures would
suggest the inability of the PTDMs to escape endosomes over short periods of time, it is
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difficult to exclude some PTDM endosomal escape since these fewer dispersed molecules
would appear much dimmer by CLSM analysis.
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Figure 0.4. Effects of concentration on FITC labeled polymer internalization.
Concentration dependence for MePh10-b-dG5 and R8 labeled with FITC at 5, 10, and
20 µM (A). HeLa cells were treated with 1 hour with PTDMs and imaged with a
CLSM and assessed for MFI (B) and viability (C) using flow cytometry.
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2.3.5. EGFP Delivery
Polymers were tested for transduction efficiency with enhanced green fluorescent
protein (EGFP) as an indication of internal cell location and delivery efficiency. The
PTDMs and protein were incubated for 30 minutes to allow for the formation of noncovalent complexes and then applied drop-wise to HeLa cells. At four hours, all
homopolymer PTDMs and R8 proved to be ineffective at delivering protein into the cell,
showing limited uptake in both the microscope images and FCM data (Figure 0.5). The
block copolymer showed significantly higher internalization, but was still punctate,
suggesting entrapment in endosomes within the observed time periods. None of the PTDMs
or R8 showed any cytotoxic effects compared to the untreated sample, as determined by
7AAD during flow analysis. While the lack of delivery with the diester homopolymer
PTDMs was unsurprising because of their poor internalization with the dye, it is interesting
that PGON20 was unable to facilitate protein internalization. This could be attributed to its
lack of a defined hydrophobic segment. MePh10-b-dG5 was expected to have high delivery,
as R8 has been shown to be more effective with a hydrophobic component attached.193 As
demonstrated here and by others, the hydrophobic domain of the PTDM is important to
protein internalization.193,194 The block copolymer outperformed all other polymers tested
at protein delivery yielding an MFI around 20 times higher, as determined by FCM (Figure
0.5B). This was corroborated with confocal images, which revealed both punctate and
diffuse fluorescence within the imaged cells (Figure 0.5A).
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Figure 0.5. EGFP delivery into HeLa cells with unlabeled PTDMs. EGFP was
complexed with PTDMs for 30 minutes at a molar ratio of 20:1. HeLa cells were
treated with the complexes for four hours to observe internalization. Cells were
imaged using a CLSM (A). Internalization efficiency as determined by MFI (B) and
percent uptake (C) was confirmed using FCM to quantitate the delivery of EGFP.
Complexed MePh10-b-dG5 with protein was tested in relation to non-complexed
polymer and protein compared to R8 with and without the protein (D).
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Additionally, complex formation was tested to determine if the PTDMs merely
compromise the cell membrane allowing protein into the cytosol, or if they actively
facilitate transport across the membrane. Cells were treated with MePh10-b-dG5 and R8
complexed with protein for 30 minutes at room temperature and were compared with cells
treated directly with the PTDMs followed by protein, which were given no time to form a
complex. The flow cytometry data, highlighted in Figure 0.5C, showed internalization for
the cells treated with MePh10-b-dG5 and protein complex, but not for those treated with
the PTDMs and protein independently. This suggests that MePh10-b-dG5 does not merely
interact with the membrane to allow indiscriminant uptake of proteins in the cytosol, but
rather an incubation time is required for the PTDMs to form complexes with the proteins.
2.4. Conclusion
While determining the predominant mode of internalization for CPPs remains a
challenge, using PTDMs to advance the understanding of how structure influences uptake
activity is critical to improving design parameters for efficient internalization. By
examining changes in molecular composition in relation to their ability to enter cells when
complexed with cargo, PTDMs can be enhanced to deliver specific molecules into the cell.
Here, we performed common methods to assess internalization mechanisms and efficiency
for guanidinium-containing PTDMs both alone and non-covalently complexed to cargo.
This provides the first side-by-side studies for this class of PTDMs and R8 with respect to
cellular internalization. Homopolymer PTDMs proved to be inefficient at entering cells,
with the exception of PGON20, which was even able to enter cells at a higher capacity than
the block copolymer PTDM MePh10-b-dG5. Increasing the concentration of the PTDMs
led to improved internalization but also to higher cytotoxicity, a common observation

61

across PTDMs. None of the homopolymer PTDMs were able to facilitate the delivery of
EGFP, while MePh10-b-dG5 proved to be exceptionally efficient. Additionally, MePh10b-dG5 was the only polymer that also localized with late endosomes, suggesting endosomal
entrapment for some of the complexes on the time scale used in this study. This finding
highlights the importance of hydrophobic segments for efficient cargo delivery by PTDMs
and that these structural changes influence the balance of pathways. These polymers
remained punctate in the case of internalization for FITC-labeling and protein delivery,
suggesting that endosomal uptake is the predominant mode of internalization. Findings will
contribute to future design considerations for intracellular delivery systems and aid in our
understanding of the modes of internalization for arginine-rich molecular transporters.
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CHAPTER 3
INCREASED HYDROPHOBIC BLOCK LENGTH OF PTDMS PROMOTES
PROTEIN INTERNALIZATION
3.1. Introduction
The plasma membrane plays a crucial role in cell survival, acting as a selectively
penetrable barrier limiting large macromolecules from entering the cytoplasm.195 As the
field of molecular biology expands, investigation of intracellular processes is often
hampered by the inability of biomacromolecules, such as proteins and antibodies, to
efficiently and selectively cross the cell membrane.11 The use of protein transduction
domains (PTDs), sometimes referred to as cell penetrating peptides (CPPs), to facilitate the
delivery of large biological cargo can be used to overcome this barrier.10,11,196 PTDs are
generally short, cationic protein segments with the ability to traverse the phospholipid
bilayer.197 The first protein discovered with this ability was the HIV-1 TAT protein.163,164
Subsequent studies found that TAT’s ability to translocate the membrane was largely due
to the arginine rich domain between residues 48 – 60.165 Guanidinium groups, such as those
present in polyarginine, have since been shown to be important in facilitating
translocation.111,176 Through studying TAT and several other naturally occurring PTDs,
along with their structural derivatives, it became apparent that secondary protein structure
and peptide based backbones are not essential requirements for efficient cellular uptake,
but that charge content is critical with guanidine functionality being particularly
efficient.111,112,165,198–200 Consequently, a large number of highly charged, cationic PTD
mimics (PTDMs) have been reported.167,201–207
More recently, addition of a hydrophobic domain has been shown to improve
membrane transduction activity.208 Examples of this are N-terminal stearylation/acylation
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of polyarginine, 24 and the use of supramolecular, hydrophobic counter ions,176,209,210 which
improve both membrane affinity and cellular internalization. Inherently amphiphilic CPPs,
such as penetratin, have also provided a source of inspiration for chimera mimics like Pep1.119,161,211 Additionally, aromaticity has also been shown to play a role in membrane
interactions and translocation;212–214 oligoarginine activity has been enhanced with the use
of aromatic counter ions, and with the incorporation of tryptophan or phenylalanine in the
peptide sequences.215–218
Given the importance of aromatic amino acids in membrane proteins and their
unique interactions with the bilayer, it was proposed that aromatic side chains would make
better activators than other hydrophobic amino acids, given equal relative
hydrophobicity.111,219,220 We have previously reported the synthesis and preliminary
investigations of oxanorbornene based guanidinium rich polymer mimics of polyarginine,
which have shown higher membrane activity compared to their polyarginine
counterparts.187–189 Aromatic groups have been studied in peptide based CPPs and the role
of hydrophobicity has been further explored for protein delivery using PTDMs.186,221 More
specifically, constitutional macromolecular isomers have been used to investigate the
importance of sequence segregation for protein delivery, instilling the importance of a
distinct hydrophobic domains.134 Herein, we have designed and characterized eight
different block-copolymer PTDMs inspired by polyarginine and amphiphilic peptides to
deliver protein via non covalent complexes into HeLa cells, as well as two hard to transfect
cell types, Jurkat T cells, and hTERT MSCs, thus providing critical information regarding
the importance of hydrophobicity in PTDM delivery systems.
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Polymer mimics offer distinct advantages over peptide derivatives of PTDs in that
they are functionally and structurally versatile. In our previously reported synthetic
approach, we achieved well-defined PTDMs with control over the spatial arrangement of
positive charges and hydrophobic groups. These molecules were obtained using ringopening metathesis polymerization (ROMP), a technique well known for its highly
controlled nature, functional group tolerance, and rapid polymerization times. Here, we
extend this platform to access a series of block copolymers with precise hydrophobic and
cationic content and density.134,185–187,191,221,222 Control over monomer hydrophobic content
also enables deconvolution of side chain hydrophobicity from the hydrophobicity imparted
by the polymer backbone. Using HPLC to determine the relative hydrophobicity of the
monomers allows us to relate the hydrophobic content of each polymer, in terms of length,
with their ability to deliver cargo.
Attachment of cargo via covalent linkage is often required for efficient use of
PTDs.128,223,224 The polymers studied here are able to form stable, non-covalent complexes
with their associated cargos that are then internalized into cells.188 In the context of
promoting fundamental studies, non-covalent interactions are preferred due to their
simplicity, delivery efficiency, and minimization of labor.225 To evaluate the ability of
these protein-containing complexes to enter cells, enhanced green fluorescent protein
(EGFP) was chosen as a cargo. Flow cytometry was used to determine both the percentage
of cells that receive the cargo, as well as the extent of uptake in the cells of interest.
Additionally, cell viability was assessed after treatment, though very little toxicity was seen
from any of the polymer-protein complexes.
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In general, we found that a high density of cationic charge with a longer
hydrophobic block led to higher levels of uptake. While some hydrophobic content
threshold was required, the overall hydrophobic density seemed to have less of an impact
than cationic density or length of the hydrophobic block on the ability of the block
copolymers to efficiently internalize cargo. From this it has been hypothesized that
increased hydrophobic block length creates a more stable interaction with the cargo protein.
Similar results were found across all three cell types suggesting that this trend is applicable
to all ROMP-based oxanorbornene block copolymers. The structure-activity study of these
PTDMs provides guidance for building polymers that enable more efficient delivery of
cargo, such as proteins, as tools to probe intracellular pathways.
3.2. Materials and Methods
3.2.1. PTDM Synthesis
3.2.1.1.

Monomers

Similar to monomer synthesis in section Error! Reference source not found., all f
ive monomers were synthesized following the procedure introduced by Lienkamp et. al.192
In general, the Diels-Alder adduct 1 was obtained by the reaction of maleic anhydride with
furan in toluene. As following Lienkamp et al., the monomers were synthesized from 1
under similar conditions:
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∆

O

O

3 Days

O
1

O

HO-R1

O

O

(i) DMAP - RT, overnight
(ii) HO-R2, DMAP - RT to 0˚C
(iii) EDC: 0˚C to RT, overnight

HO
O

R1

OH-R =

NBoc
NHBoc

HO

O
O

H
N

R2

dG: 1 was dissolved in the minimum amount of dry DCM together with 2 eq. of 1,2-DiBoc-2-ethyl guanidine, and 10 mol% 4-dimethylaminopyridine (DMAP). The temperature
was

lowered

to

0°C

with

an

ice

66

bath

and

1

eq.

of

1-ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC) was added, then stirred over night at room
temperature. After completion of the reaction, the solution was concentrated and the
product was purified via column chromatography with silica gel using DCM/ethyl acetate
(8:2) as eluent. Vacuum evaporation of the solvent yielded the pure product with a yield of
~60%.
1

H NMR (300 MHz, CD3CN): δ 11.54 (s, 2H), 8.35 (s, 2H), 6.44 (s, 2H), 5.17 (s, 2H), 4.33

– 3.97 (m, 4H), 3.72 – 3.41 (m, 4H), 2.82 (s, 2H), 1.48 (s, 9H), 1.42 (s, 9H); 13C NMR (75
MHz, CD3CN): δ 172.43, 164.51, 157.35, 153.72, 137.56, 84.05, 81.41, 79.50, 63.72,
47.49, 40.21, 28.38, 28.09; HR-MS (FAB) m/z [M+H]+: 755.3827 (calc.), 755.3824
(found).
MeG: 1 was dissolved in the minimum amount of dry DCM together with 1 eq. of 1,2-DiBoc-2-ethyl guanidine, and 10 mol% DMAP. The temperature was lowered to 0°C with an
ice bath and 1 eq. of EDC was added, then stirred over night at room temperature. The half
ester was precipitated from solution, isolated using vacuum filtration, and washed with
cold DCM followed by drying on vacuum overnight. The half ester, one equivalent of
MeOH. and 10% DMAP were dissolved in DCM and stirred at RT under nitrogen. After
completion of the reaction, the solution was concentrated and the product was purified via
column chromatography with silica gel using DCM/ethyl acetate (8:2) as eluent. Vacuum
evaporation of the solvent yielded the pure product with a yield of ~80%.
1

H-NMR (300 MHz, CDCl3): δ=11.50 (1H, s), 8.55 (1H, s), 6.46 (2H, s), 5.3 (2H, d, J=6.0

Hz), 4.25 (2H, m), 3.72 (5H, m), 2.84 (2H, s), 1.49 (18H, s).13C-NMR (75 MHz, CDCl3):
δ= 171.7, 171.5, 163.4, 156.3, 153.1, 136.6, 83.2, 80.7, 80.6, 79.4, 63.5, 52.4, 47.1, 46.6,
39.4, 28.3, 28.1. HR-MS (FAB): calc. 483.22, found 484.23.
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dPh: 1 was dissolved in the minimum amount of dry DCM together with 2 eq. of benzyl
alcohol, and 10 mol% DMAP. The temperature was lowered to 0°C with an ice bath and 1
eq. of EDC was added, then stirred over night at room temperature. After completion of
the reaction, the solution was concentrated and the product was purified via column
chromatography with silica gel using DCM/ethyl acetate (8:2) as eluent. Vacuum
evaporation of the solvent yielded the pure product with a yield of ~88%.
1

H NMR (300 MHz, CD3CN): δ 7.34 (d, J = 3.0 Hz, 10H), 6.44 (s, 2H), 5.16 (s, 2H), 4.97

(dd, J = 45.5, 12.4 Hz, 4H), 2.87 (s, 2H); 13C NMR (75 MHz, CD3CN): δ 172.37, 137.52,
137.03, 129.41, 129.14, 129.06, 81.30, 67.26, 47.58; HR- MS (FAB) m/z [M+H]+:
365.1389 (calc.), 365.1398 (found).
MePh: One equivalent of 1 and 1.25 equivalents of the corresponding substituted benzyl
alcohol, and 10 mol% DMAP were dissolved in minimal amounts of distilled DCM and
the reaction mixture was stirred under nitrogen at room temperature overnight. The half
ester was precipitated from solution, isolated using vacuum filtration, and washed with
cold DCM followed by drying on vacuum overnight. The half ester, one equivalent of
MeOH. and 10% DMAP were dissolved in DCM and stirred at RT under nitrogen. The
solution was then cooled down to 0˚C and one equivalent of EDC was added. The solution
as stirred overnight under nitrogen at room temperature. The reaction mixture was then
collected by rotoevaporation and purified by column chromatography with DCM/ethyl
acetate (8:2). the sample was dried under vacuum over night to obtain a pure white solid
(yield 82%).
1

H NMR (300 MHz, CD3CN): δ = 7.38 (comp, 5H), 6.44 (comp, 2H), 5.14 (d, 2H), 5.06

(comp, 2H), 3.50 (s, 3H), 2.84 (q, 2H).13C NMR (75 MHz, CD3CN): δ = 173.35, 172.84,
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137.95, 137.91, 137.51, 129.84, 129.60, 129.50, 81.64, 81.63, 67.72, 52.75, 47.96, 47.89.
HR-MS (FAB) m/z [M+H]+: 289.1076 (calc.), 289.1078 (found).
dMe: 1 was dissolved in the minimum amount of dry DCM together with 2 eq. of MeOH,
and 10 mol% DMAP. The temperature was lowered to 0°C with an ice bath and 1 eq. of
EDC was added, then stirred over night at room temperature. After completion of the
reaction, the solution was concentrated and the product was purified via column
chromatography with silica gel using DCM/ethyl acetate (8:2) as eluent. Vacuum
evaporation of the solvent yielded the pure product with a yield of ~84% (6).
1

H NMR (500 MHz, DMSO): δ = 6.46 (s, 2H), 5.11 (s, 2H), 3.55 (s, 6H), 2.82 (s, 2H). 13C

NMR (125 MHz, DMSO): δ = 171.70, 136.61, 79.74, 51.63, 46.23. HR-MS (FAB) m/z
[M+H]+: 213.0763 (calc.), 213.0749 (found).
3.2.1.2.

Polymers

Reaction conditions for block copolymer synthesis: Monomer dG, monomer
MePh, and G3 catalyst were dissolved in dry DCM in respective schlenk flasks, purged
with nitrogen, and subjected to three freeze-pump-thaw cycles. Monomer dG solution was
added into the catalyst solution via syringe all at one time. The brown solution was stirred
for 30 minutes at room temperature before monomer MePh was introduced. After stirring
for an additional 2 hours, the reaction was terminated with 1 mL of ethyl vinyl ether and
stirred for 30 minutes. DCM was evaporated and the product was dissolved in minimal
DCM and loaded on a short silica gel column (7 cm length, 3 cm diameter). The unreacted
end-group and any side products were washed from the column with DCM, while polymer
remained on the column and was recovered with ethyl acetate. Ethyl acetate was
evaporated to yield the pure product. Block co-polymers were characterized by 1H NMR
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along with THF GPC using a polystyrene standard (Error! Reference source not found.) t
o determine block length and ratio.
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dPh5-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.66 (2H, br), 8.47 (2H, br), 7.32 (12H,
br), 5.98 (trans) and 5.68 (cis) (4H total, br), 5.21 (4H, br), 5.01 (cis) and 4.74 (trans) (4H
total, br), 4.25 (4H, br), 3.69 (4H, br), 3.27 (4H, br), 1.46 (18H, s), 1.41 (18H, s).
MePh10-b-dG5: 1H-NMR (500 MHz, CDCl3): d 11.57 (2H, br), 8.40 (2H, br), 7.37 (6H,
br), 5.80 (trans) and 5.61 (cis) (4H total, br), 5.08 (2H, br), 5.00 (cis) and 4.77 (trans) (4H
total, br), 4.66 (2H, br), 4.17 (4H, br), 3.64 (4H, br), 3.49 (3H, br), 3.17 (4H, br), 1.46 (18H,
s), 1.41 (18H, s).

dPh5-b-MeG10: 1H-NMR (500 MHz, CDCl3): d 11.52 (1H, br), 8.31 (1H, br), 7.33 (12H,
br), 5.84 (trans) and 5.60 (cis) (4H total, br), 4.99 (4H, br), 4.90 (cis) and 4.60 (trans) (4H
total, br), 4.17 (2H, br), 3.62 (3H, br), 3.49 (2H, br), 3.13 (4H, br), 1.44 (9H, s), 1.41 (9H,
s).
MePh10-b-MeG10: 1H-NMR (500 MHz, CDCl3): d 11.55 (1H, br), 8.42 (1H, br), 7.34 (6H,
br), 5.82 (trans) and 5.61 (cis) (4H total, br), 5.03 (2H, br), 5.00 (cis) and 4.76 (trans) (4H
total, br), 4.59 (2H, br), 4.14 (6H, br), 3.62 (2H, br), 3.51 (4H, br), 3.14 (9H, br), 1.44 (9H,
s), 1.40 (18H, s).
dPh10-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.56 (2H, br), 8.39 (2H, br), 7.33 (12H,
br), 5.88 (trans) and 5.62 (cis) (4H total, br), 5.10 (2H, br), 5.03 (cis) and 4.66 (trans) (4H
total, br), 4.18 (2H, br), 3.60 (4H, br), 3.15 (4H, br), 1.46 (18H, s), 1.43 (18H, s).
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MePh5-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.66 (2H, br), 8.47 (2H, br), 7.32 (6H,
br), 5.98 (trans) and 5.68 (cis) (4H total, br), 5.21 (4H, br), 5.01 (cis) and 4.74 (trans) (4H
total, br), 4.25 (4H, br), 3.69 (4H, br), 3.27 (4H, br), 1.46 (18H, s), 1.41 (18H, s).
dMe5-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.59 (2H, br), 8.39 (2H, br), 5.93 (trans)
and 5.67 (cis) (4H total, br), 5.08 (4H, br), 4.90 (cis) and 4.70 (trans) (4H total, br), 4.23
(6H, br), 3.65 (4H, br), 3.18 (4H, br), 1.46 (18H, s), 1.41 (18H, s).
dMe10-b-dG5: 1H-NMR (500 MHz, (CD3)2CO): d 11.56 (2H, br), 8.38 (2H, br), 5.89
(trans) and 5.59 (cis) (4H total, br), 5.07 (4H, br), 5.96 (cis) and 4.69 (trans) (4H total, br),
4.21 (6H, br), 3.61 (4H, br), 3.22 (4H, br), 1.51 (18H, s), 1.47 (18H, s).
Table 0.1. Molecular weight of polymer series determined by gel permeation
chromatography in tetrahydrofuran (THF) using a polystyrene standard.
Polymer

Mn

Mw

Mp

PDI

dPh5-b-dG5

9488

10123

10103

1.067

MePh10-b-dG5

5612

6071

6166

1.082

dPh5-b-MeG10

9965

10609

10782

1.065

MePh10-b-MeG10 11063

12060

12277

1.090

dPh10-b-dG5

9496

10265

10565

1.081

MePh5-b-dG5

5412

5744

5743

1.061

dMe5-b-dG5

5078

5392

5438

1.062

dMe10-b-dG5

6366

7011

7380

1.10

3.2.1.3.

Deprotection

The polymers were dissolved in 2 mL DCM and 2 mL trifluoroacetic acid (TFA)
for deprotection. After stirring overnight, the excess acid was removed by azeotropic
distillation with methanol. After complete evaporation of the acid, samples were dissolved
in water/methanol mixture and dialyzed against RO water until the conductivity of water
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was ~0.1µS. The deprotected copolymer was recovered by lyophilization. Final
deprotected polymer was stored at -20 ºC.
3.2.2. Characterization
3.2.2.1.

Reverse Phase High Liquid Chromatography

Water and acetonitrile were each prepared with 0.1% TFA for the liquid phase.
Monomers were prepared at 5 mg/mL in DMSO, which also served as the flow marker.
Samples were loaded onto a C8 reverse phase column held at room temperature and run at
a gradient of 100% water to 100% acetonitrile over 60 minutes. Each sample was followed
by 15 minutes of equilibration back to water prior to loading of the next sample.
3.2.2.2.

Dynamic Light Scattering

dPh10-b-dG5, MePh10-b-dG5, and dMe10-b-dG5 were dissolved in DMSO and
brought to a final concentration of both 5 mg/mL and 2.5 mg/mL. Samples were subjected
to dynamic light scattering (DLS) at 10 degree intervals between 30 and 90 degrees. An
exponential decay was fit to the data to calculate the Rg values of the polymers. Exponential
fits can be found in Figure 0.4.
3.2.3. Protein Delivery
3.2.3.1.

Suspension Cells

Jurkat T cells, a human T lymphocyte leukemia cell line (clone E6-1, ATCC TIB152), were grown in RPMI 1640 supplemented with 10%(v/v) FBS, L-glutamine, nonEssential amino acids (NEAA), Na-pyruvate, 100 U/mL penicillin, and 100 U/mL
streptomycin at 37˚C, 5% CO2 and were passaged 24 hours before treatment. Polymers
were mixed with 2 µg of EGFP at a ratio of 20:1 polymer to protein and allowed to complex
for 30 minutes. Jurkats were harvested and suspended in fresh complete media and placed
into a 12 well plate at 4X105 cells/mL. PTDM – protein complexes were applied drop-wise
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into each well. Cells were treated for 4 hours, then washed 3 times with 20 U/mL heparin
in PBS before being suspended in 0.2% BSA FACS buffer and stained with 7-AAD. EGFP
internalization and viability were assessed by flow cytometry using a BD® LSR-II. EGFP
fluorophores were excited at 488 nm, and fluorescence was measured at 530 nm. The
fluorescence signal was collected for 10,000 cells and viable cells were gated on to obtain
a histogram of fluorescence intensity per cell. Live cells were assessed for their median
fluorescence intensity (MFI) and their total positive shift in fluorescence (% positive).
Internalization and delivery was repeated in three independent experiments. Statistical
analysis was performed using the one way ANOVA and Tukey post hoc test to determine
significance between polymers.
3.2.3.2.

Adherent Cells

HeLa (human) and hTERT mesenchymal stem cells (MSCs) were grown at 37˚C
with 5% CO2 in DMEM supplemented with 10%(v/v) FBS, 100 U/mL penicillin, and 100
U/mL streptomycin. Cells were plated at 5X104 cells/mL in a 12 well plate 48 hours before
treatment for FACS analysis or 1X106 cells in a 35 mm glass bottom plate for CLSM.
Polymers were mixed with 2 µg of EGFP at a molar ratio of 20:1polymer to protein and
allowed to complex for 30 minutes during which cells were aspirated and covered in fresh
complete media. PTDM–protein complexes were applied drop-wise into each well. After
4 hours of treatment, cells were aspirated and lifted with 0.1% trypsin, then treated with
complete media to bind excess trypsin. Cells were then washed 3 times with 20 U/mL
heparin in PBS before being suspended in 2% FBS FACS buffer and stained with 7aminoactinomycin D (7-AAD). Similar to the Jurakts, EGFP internalization and viability
were assessed by flow cytometry under the same conditions.
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3.2.3.3.

Confocal Laser Scanning Microscopy

HeLa cells were seeded at 106 cells/ 2 mL of a-MEM with 10% FBS on 35 mm
glass bottom plates and 105 cells/ 1 mL on 12-well plates 48 hours prior to treatment and
cultured at 37˚C and 5% CO2. Polymer was complexed with 2 µg of protein at a ratio of
20:1 polymer to protein for 30 minutes, during which the cells were aspirated and covered
in fresh complete media. Cells were treated for 4 hours with the polymer protein complexes
in a total volume of 1 mL a-MEM with 10% FBS. Before imaging, cells were washed three
times with cold media and covered in 1 mL fresh cold a-MEM with 10% FBS. Cells were
imaged using a FV300 CSLM Olympus IX81 microscope at 60X.
3.3. Results and Discussion
3.3.1. PTDM Design
The presence of guanidinium groups and hydrophobic moieties in PTDs and
PTDMs has previously been reported as crucial for protein delivery.194 To investigate the
role of hydrophobicity and charge density, a series of monomers with varying hydrophobic
and cationic content was synthesized (Figure 0.1). The hydrophobic magnitude of
monomers in Figure 0.1B was assessed using reverse phase HPLC. The di-methyl (dMe)
monomer had the lowest retention time (13.8 minutes), whereas methyl-phenyl (MePh),
with an added benzene ring, had an intermediate retention time (27.5 minutes) and the diphenyl monomer (dPh) had the longest retention time (35.9 minutes) (Error! Reference s
ource not found.). These retention times indicate that the addition of phenyl groups to the
monomer increases hydrophobic content and is thus translatable to the hydrophobic content
of the polymers. Two guanidine containing monomers, methyl-guanidine (MeG) and di-
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guanidine (dG), were also designed in order to investigate the role of cationic density
within the positively charged block of the polymers.
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Figure 0.1. Oxanorbornene monomers used in this study. A) Guanidine containing
monomers methyl guanidine (MeG) and di-guanidine (dG), with blue representing
the cationic substituent and grey for the added methyl. B) Hydrophobic monomers
di-methyl (dMe), Methyl-phenyl (MePh), and di-phenyl (dPh), with green
representing the most hydrophobic components. C) Reverse-phase HPLC
chromatographs for dMe, MePh, and dPh monomers elucidating relative
hydrophobicity.
These difunctional monomers were polymerized by ROMP to yield low dispersity
(Ɖ) oxanorbornene block copolymers. GPC traces showed a complete shift in the final
diblock toward a higher molecular weight compared to the first block, illustrating
controlled polymerization for efficient chain extension. All polymers had narrow Ɖ values
(≤ 1.1) as determined by GPC, and a phenyl to guanidine ratio consistent with expectations,
as determined by 1H NMR spectroscopy.
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A series of four block copolymers was created comprised of a first block with ten
phenyl substituents and a second block with ten guanidine substituents. Within these
samples, however, the density of these functional groups is varied using the smallest methyl
substituent to add space between hydrophobic or cationic groups. These are depicted in
Figure 0.2 as dPh5-b-dG5, MePh10-b-dG5, dPh5-b-MeG10, and MePh10-b-MeG10. This
set of polymers was designed to explore the effect of varying charge and hydrophobic
density along the polymer backbone on the ability of the PTDMs to deliver protein into
HeLa, hTERT MSC, and Jurkat T cells.
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Figure 0.2. Structures and cartoons of a polymer series with varying cationic and
hydrophobic density. Each polymer contains 10 phenyl groups represented in green
and 10 guanidinium groups represented in blue. The density of the hydrophobic and
cationic groups is varied using a methyl substituent (grey).
To further investigate the effect of hydrophobic moieties and backbone contribution
on protein delivery, the series was expanded to include another set of polymers that hold
the high guanidinium density (dG5) constant but vary hydrophobic density (either dPh,
MePh, or dMe) and length (5 or 10) to compliment the initial polymer set. For example,
dPh10-b-dG5 has high hydrophobic density (dPh) with a length of ten to match the
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backbone length of the longest hydrophobic block (MePh10-b-dG5); MePh5-b-dG5 was
added to distinguish between added backbone length and decreased hydrophobic density
(juxtapose MePh10-b-dG5 and dPh10-b-dG5); lastly, dMe5-b-dG5 and dMe10-b-dG5 were
included as controls to mimic the length of the backbone added by the hydrophobic blocks,
while minimizing the hydrophobicity of the substituents. This second series of other
polymers, displayed in Figure 0.3, was specifically designed to decouple hydrophobic
block length from hydrophobic content with respect to protein delivery.
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Figure 0.3. Structures and cartoons of the second polymer series with varying
hydrophobic density and length. dPh5-b-dG5 and MePh10-b-dG5 are repeated from
Figure 0.2 for ease of comparison. Hydrophobic phenyl substituents are represented
in green, cationic moieties in blue, and methyl groups in grey.
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3.3.2. Dynamic Light Scattering
Dynamic light scattering was performed on dPh10-b-dG5, MePh10-b-dG5, and
dMe10-b-dG5 to determine whether these molecules self-assemble in an aqueous
environment Figure 0.4. These three polymers were chosen to compare the maximum
hydrophobic block lengths with varying phenyl group density. While this is not a direct
indication of their ability to interact with cargo or transverse the membrane, it is important
to understand whether they present a “hydrophobic core” in which the protein might reside
or act as individual, solvated chains. dMe10-b-dG5 had an Rh of 33 nm, MePh10-b-dG5 had
an Rh value of 67 nm, and the relaxation curves (Figure 0.4) for dPh10-b-dG5 indicated a
polydisperse Rh fit of 29 nm showing that all three block copolymers self-assemble in
aqueous solution. Given that the overall sizes are similar despite the variation in
hydrophobic side chain suggests that the overall block architecture is more important to
driving assembly than the side chain composition. Both polymers containing phenyl side
chains had broader distributions, so it is possible that the side chains have some influence
on the nanoparticles internal organization. Nevertheless, from these findings it can be
hypothesized that the self-assembled aggregates provide a hydrophobic domain that allows
the polymers to complex their cargo while the role of electrostatic interactions remains
unclear given the phosphate buffer solution in which they are formed contains around 150
mM of salt.
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Figure 0.4. Dynamic light scattering curves (top) for dMe10-dG5, MePh10-dG5, and
dPh10-dG5 overlayed with their CONTIN fits (bottom) used to predict the radius of
hydration. Measurements were taken at 30˚, 40˚, 50˚, and 60˚ and used together for
the prediction.
3.3.3. Protein Delivery
The ability of the polymers to facilitate the internalization of EGFP into cells was
investigated in Jurkat T cells, HeLa cells, and hTERT MSCs. To assess protein delivery
and viability, cells were analyzed using flow cytometry. In addition, confocal microscopy
was used to image uptake into HeLa cells for the first series of polymers (Figure 0.2).
Trends were relatively consistent across the three cell lines with respect to their percent
uptake, median fluorescence intensity (MFI), and viability profiles. While all polymers
tested were able to deliver consistently into greater than 50% of the cell populations (SI),
the amount of protein delivered, determined by MFI, varied based on the polymer and, to
a limited extent, cell type. Cell viability was above 95% in both HeLa and Jurkats, but
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slightly decreased to just above 80% for dPh5-b-dG5 and MePh10-b-dG5 in the hTERT
MSCs as seen in Figure 0.5.
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Figure 0.5. Cellular viability after cells were treated with 2 µg of protein at a 20:1
polymer to protein molar ratio for 4 hours, as determined by 7AAD staining
compared with an untreated sample. Viability is above 90% in all cases, except with
the MePh10-dG5 and dPh10-dG5 in the hTERT MSCs which are higher than 85%.
The MFI (Figure 0.6) in all cell types, as established by flow cytometry, showed
that MePh10-b-dG5, containing the high cationic density dG monomer, yielded greater
internalization than its counterpart, MePh10-b-MeG10, with the MeG monomer. This
indicates that increasing the cationic density of the block copolymer improves protein
internalization, corroborating the suggestion that high guanidine density is important for
membrane interactions and therefore delivery.187 It should be noted that while there was no
statistical difference between delivery using dPh5-b-dG5 and dPh5-b-MeG10, the
fluorescent shift appears higher for the more cationically dense polymer (dPh5-b-dG5) in
Jurkats, suggesting that similar correlations could be drawn from this more sensitive cell
line. These findings were additionally confirmed by images taken with CLSM of HeLa
cells treated with the polymer-protein complexes, Figure 0.7, which revealed both punctate
and diffuse fluorescence within the cells.
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Figure 0.6. Representative histograms (top) compared to a blank (grey) and the
corresponding median fluorescence intensity (bottom) for EGFP delivery with
MePh10-b-MeG10, MePh10-b-dG5, dPh5-b-MeG10, and dPh5-b-dG5 into HeLa, Jurkat
T cells, and hTERT MSCs. Cells were treated with 2 µg of protein at a 20:1 polymer
to protein molar ratio for 4 hours, then washed with heparin to remove membrane
bound proteins. A shift to the right from the grey blank in the histograms indicates
higher fluorescence and was used to establish the median fluorescence intensity (MFI)
as well as the percent uptake.
While all four polymers yielded a complete shift in the fluorescence population of
the cells, the MFI was 10X higher when using MePh10-b-dG5 in all three cell types.
Surprisingly, increasing hydrophobic density did not improve the ability of the polymers
to deliver protein into any of the cell types, as seen by comparing dPh5-b-dG5 with
MePh10-b-dG5. With MePh10-b-dG5 able to deliver the most protein (MFI ranging
between 3000 to 4000) into the highest percentage of cells (around 95% depending on the
cell type), high cationic density coupled with a lower density hydrophobic block appeared
to optimize protein internalization. However, these comparisons alone do not fully
decouple hydrophobic density of the monomer functional groups from potential
hydrophobic effects related to the length. To explore this specific relationship, the series
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was expanded to include dPh10-b-dG5, MePh5-b-dG5, dMe5-b-dG5, and dMe10-b-dG5, as
shown in Figure 0.3.
dPh5-b-dG5

MePh10-b-dG5

dPh5-b-MeG10

MePh10-b-MeG10

Figure 0.7. CLSM images of EGFP delivery into HeLa cells by MePh10-b-MeG10,
MePh10-b-dG5, dPh5-b-MeG10, and dPh5-b-dG5. Cells were treated with 2 µg of
protein at a 20:1 polymer to protein ratio for 4 hours, and then washed 3 times to
remove excess protein.
These polymers all contain a cationic dG block length of 5, since high cationic
density appears to be more optimal for protein delivery. Higher internalization was seen
when the dPh block length was increased from 5 to 10 (dPh10-b-dG5) yielding a higher
MFI and effecting a higher percentage of the cell population in all cell types. Decreasing
the MePh block length from 10 to 5 (MePh5-b-dG5) reduced delivery and the percentage
of cells that received protein. More specifically, in Jurkats but not HeLa or the MSCs, there
is an added advantage of using dPh10-b-dG5 as it results in almost two fold higher MFI
than MePh10-b-dG5. This difference highlights the tunability of this polymer platform to
address specific cell types. Any additional hydrophobicity introduced by increasing the
length of the polymer was investigated by replacing the phenyl substituents with methyl
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groups (dMe5-b-dG5 and dMe10-b-dG5). These polymers showed moderate protein
delivery to a high number of cells, but the amount of protein delivered was far less than
their phenyl containing counterparts (Figure 0.8). This indicates that, in addition to
increased block length, the presence of a threshold hydrophobicity is important for efficient
cellular internalization of this cargo.
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Figure 0.8. Representative histograms and the corresponding median fluorescence
intensity for EGFP delivery with dMe5-b-dG5, dMe10-b-dG5, MePh5-b-dG5, MePh10b-dG5, dPh5-b-dG5, and dPh10-b-dG5 into HeLa, Jurkat T cells, and hTERT MSCs.
Cells were treated with 2 µg of protein at a 20:1 polymer to protein molar ratio for 4
hours, then washed with heparin to remove membrane bound proteins. A shift to the
right from the grey blank in the histograms indicates higher fluorescence and was
used to establish the median fluorescence intensity (MFI) as well as the percent
uptake.
The ability to deliver proteins is substantially amplified when the hydrophobic
block length is increased for the two phenyl-containing monomers (MePh, dPh),
regardless of cell type. Both adherent cell types showed insignificant differences in MFI
between MePh10-b-dG5 and dPh10-b-dG5, while Jurkats were sensitive to the hydrophobic
substituents with dPh10-b-dG5 outperforming MePh10-b-dG5. Further investigation with
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other cell types, both adherent and suspension, might provide insight into this difference.
Additionally, other polymer series with different hydrophobic substituents may help
determine if the aromaticity of the phenyl group is indeed crucial, or cell type dependent.
Lastly, optimization with different cargos would allow for further development and
specificity of this polymer platform for increased internalization of proteins and antibodies
into hard to transfect cell types.
3.4. Conclusion
Oxanorbornene block copolymers with varying cationic and hydrophobic density
but the same charge and hydrophobic content were synthesized and characterized. While
all of the PTDMs displayed the ability to deliver protein into HeLa, Jurkats, and hTERT
MSCs, increased cationic density proved to have a slight edge over those with a methyl
substituent on each guanidinium-based monomer. A second series of polymers highlighted
the importance of hydrophobic length over density, although additional hydrophobicity
from increasing the polymer backbone length does not exceed the hydrophobic threshold
that is required for protein internalization. Increasing the length of the hydrophobic blocks
may introduce better PTDM–protein interactions, facilitating delivery across the
membrane. Further studies using different cargo types such as intracellularly active
proteins would highlight the capabilities of these block copolymers.
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CHAPTER 4
SERUM SENSITIVE PROTEIN DELIVERY BY POLYMERIC PEPTIDE
MIMICS
4.1. Introduction
The field of transfection has been dominated by the delivery of DNA for
constitutive expression within the cell. The delivery of proteins into the cytosol can be
exploited to produce highly specific intracellular interactions with spatial and temporal
control.6 Results from protein transfection can be extremely fast in comparison with
traditional gene expression as it does not require transcription and translation.226 The
temporal control allows for investigation of transient effects of proteins, while avoiding
over expression or random insertion of DNA into the targeted genome.8 Protein and
antibody delivery into the cytosol provide a platform to probe intracellular pathways
involved in protein expression, transcriptional regulation, cell cycle, as well as many
others.26
To date, the concept of protein delivery has been predominantly addressed by viral
transfection, electroporation, and liposomal carriers.6 While relatively effective, these
techniques have severe limitations such as high toxicity and low efficiency that have been
addressed by the development of a category of protein delivery vehicles based on cationic
polymeric systems.7,8,114,227 While several polymer systems are currently commercially
available, often they are limited in their cargo variety, as well as the type of cell they are
able to deliver into. Additionally, almost all delivery platforms require serum free
conditions, which can be detrimental to the viability of the cells. Herein, we compare a
variety of commercially available amphiphilic polymers and peptides in their ability to
deliver GFP into HeLa, HUVEC, hTERT mesenchymal stem cells, and Jurkat T cells in
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both serum free and complete media. While most of the reagents are proprietary, the
following are descriptions of each of the carriers from their respective manufacturers.
4.1.1. Pep-1
Pep-1 was first reported by Morris et. al. to deliver proteins intracellularly using
non-covalent interactions with the macromolecule of interest.119 Since then Pep-1 and its
derivatives have been patented and are now marketed by Active Motif® under the name
Chariot™. Chariot™ claims delivery efficiency between 60-95% in less than two hours
after delivery, at which time live cells can be assayed to determine the effects of the
introduced material, without the need for fixing. According to Morris et. al. and Active
Motif®, the peptide stabilizes the protein, reducing degradation and preserving its natural
characteristics during delivery.118,119,161 After delivery, the complex dissociates, leaving the
macromolecule biologically active and free to proceed to its target organelle. Previous
reports indicate delivery occurs in the presence or absence of serum and is independent of
the endosomal pathway, which can modify macromolecules during internalization.228
Additionally, Chariot™ boasts low toxicity to the cells being transfected.
4.1.2. PULSin
PULSin™ is a cationic amphiphilic reagent designed by Polyplus Transfection®
for the delivery of peptides, antibodies and proteins into cells. The proprietary formulation
claims efficient delivery of anionic proteins and antibodies into a large variety of
eukaryotic cell lines and primary cells. PULSin™ is most efficient when able to interact
with the protein by electrostatic and/or lipophilic interactions. According to Polyplus
Transfection®, complexes are internalized via anionic cell-adhesion receptors and are
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released into the cytoplasm where they disassemble. The process is non-toxic and delivers
functional proteins, without the requirement of fixation.
4.1.3. ProteoJuice
ProteoJuice™ is a reagent produced by Novagen® owned by MerckMillipore® for
the introduction of intact functional protein into mammalian cells. ProteoJuice™ forms
non-covalent interactions with protein and has endosome protective properties ensuring
delivery of intact protein within the cell. ProteoJuice™ is compatible with delivery of
peptides and small proteins, large proteins, and even multimeric protein complexes with
minimal toxicity and broad cell specificity. Live cells can be examined less than two hours
after delivery to determine the effects of the introduced material without the need for cell
fixation.
4.1.4. Xfect
The Xfect™ Protein Transfection Reagent uses a cell-penetrating peptide
developed at Clontech® to bind and transport active proteins directly into a wide variety
of mammalian cell types, including hard-to-transfect human suspension cell lines and
mouse embryonic stem cells. Xfect™ is a modified peptide with cell-penetrating activity
whose amino acid composition enables it to interact with a protein cargo and transport this
protein across a cell membrane barrier within 2 hours.
4.1.5. Protein Transduction Domain Mimics
The amphiphilic polymeric protein transduction domain mimic (PTDM) MePh10b-dG5 was designed to mimic cell penetrating peptides incorporating a dense block of
guanidine, known for its ability to permeate cell membranes, attached to a hydrophobic
block, which has been shown to facilitate cargo delivery.134,135,229,230 Here, the
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nomenclature MePh refers to a block that contains monomers that have methyl and phenyl
substituents, and dG is constituted of two guanidine groups per monomer imparting dense
cationic charge. The Tew group has previously shown proof of concept for cellular uptake
of similar PTDMs using a fluorescent label and subsequent delivery of proteins, peptides,
and antibodies into Jurkat T cells as well as primary cells.115,134,136,187,191,229–232 The
amphiphilic nature of this PTDM allows it to form a non-covalent complex with the desired
cargo and facilitate its transport across the cell membrane in both complete media and
serum free conditions with low cytotoxicity. Internalization of the cargo has been tested as
early as 4 hours after delivery and protein function has been recorded out to 72 hours.
4.2. Materials and Methods
A total of five cationic polymer delivery vehicles were tested for their ability to
deliver GFP into a variety of cell types. Specifically, the commercially available Pep-1,
also known as Chariot™, ProteoJuice™, PULSin™, and Xfect™ were compared with our
amphiphilic polymeric peptide mimic, herein referred to as the protein transduction domain
mimic (PTDM), in both complete and serum free conditions. All purchased delivery
reagents claim non-covalent interactions with their cargo and broad cell specificity.
A variety of human cell lines were chosen to demonstrate translation across cell
types: HeLa, HUVEC, Jurkat, and hTERT mesenchymal stem cells (MSCs). HeLa cells
are the oldest and most commonly used adherent cell line and are used in many research
fields due to their stability and relative ease of transfection. HUVECs are derived from the
endothelium of veins from a human umbilical cord and have different surface properties
than many other cell lines. Jurkat T cells are a suspension cell line of T cells that have
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proven difficult for many transfection reagents. Lastly, we used MSCs as a proof of concept
cell type whose differentiation could be affected by protein cargo delivery.
To assess the ability of protein delivery, GFP was chosen as a cargo as it is selfreporting and readily accessible to most laboratories. The amount of protein delivered was
held constant at 2 µg so that the different reagents could be compared to one another.
Uptake was assessed by flow cytometry after treatment with the complexes and subsequent
washing of the cell surface with trypsin followed by three heparin washes (20 U/mL) to
remove any complexes stuck to the cell surface.
The commercial reagents all required some optimization regarding the ratio of
reagent to protein cargo, incubation time, and cell density to improve their ability to deliver
specific proteins. Delivery conditions were optimized for each of the reagents using HeLa
and Jurkat T cells and translated across the other cell types. All adherent cells were plated
24 hours prior to transfection at respective cell densities to achieve 70-90% confluency at
the beginning of the experiment.
Even though some of the reagents claim the ability to deliver in complete media,
most suggest removal of any exogenous protein during the actual transduction. Several
suggest washing the cells up to three times with PBS to remove the presence of serum. To
accommodate this, delivery was performed on cells that had been washed two times with
PBS and then suspended with serum free media. Optimization regarding serum free
conditions revealed higher viability (using 7-AAD) if cells were treated for 2 hours and
then supplemented with complete media for an additional 2 hours. A comparison of the
reagents was also made in complete media (10% FBS) to show the effect of the presence
of serum on uptake.
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4.3. Results and Discussion
As measured by a shift in cell fluorescence in relation to the untreated control (%
Positive), all of the commercial reagents except Chariot™ were able to deliver GFP into
all four cell types effecting 80% or less of the cells as shown in Figure 0.1. As expected, a
reduction in percent positive cells was observed when the complex delivery was done in
the presence of complete media. In contrast, the median fluorescence intensity (MFI),
which is directly proportional to the amount of protein delivered was exceptionally low for
all the commercial carriers in all cell types indicating that while they were able to target
many cells, they were not able to deliver large amounts of protein into the cells.
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Figure 0.1. Delivery efficiency of 2 µg GFP into Jurkats, HeLa, hTERT mesenchymal
stem cells, and human umbilical vein endothelial cells after 4 hours of treatment in
serum free conditions or complete media with amphiphilic polymers designed for
non-covalent delivery. The top row shows the median fluorescence intensity,
signifying the amount of protein that was delivered into the cells, while the bottom is
the percentage of cells that were positive for the fluorescent cargo. Data is displayed
as the mean and SEM of three replicates.
Chariot™ showed no delivery of GFP into any of the cell types in either serum free
or complete media. Extra effort was spent optimizing for this carrier with GFP, but
regardless of conditions, it never showed substantial uptake or increase in MFI. This could
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be related to the nature of the cargo and its subsequent interactions with the peptide, since
the manufacture claims it can deliver b-galactosidase efficiently into a variety of cell types.
Moderate delivery was achieved using PULSin™, especially in serum free
conditions delivering into 40-80% of the cells. The positive shift was muted in the presence
of serum, with a smaller positive shift shown in HUVEC and MSCs. While there was a
small shift in MFI from the blank in all cell types for PULSin, it appears that the relative
shift was low when compared with the PTDM. Serum free conditions appeared to facilitate
delivery, suggesting that PULSin might not bind to the GFP very strongly and that it can
easily swap out serum proteins for the fluorescent cargo. Alternatively, the serum proteins
may help inhibit interactions with the cell membrane.
ProteoJuice™ was largely ineffective in the HeLa and HUVEC cell types but
showed around 20% delivery into Jurkats and MSCs. Uptake was not reflected in the MFI,
where ProteoJuice appears to only deliver a small amount of GFP into any of the cell types.
Unfortunately, the cell viability in Jurkats was greatly reduced in serum free conditions for
this reagent (Figure 0.2).
Xfect™ performs well in serum free conditions, delivering in up to 60% of Jurkats,
though the MFI of those cells remains low indicating low amounts of protein are delivered
into the GFP positive cells across all cell types. Only in MSCs does Xfect™ show any
delivery in complete media.

91

hTERT MSCs

HUVECs

t

5

ec
Xf

t
rio
ha
C

5

ec
Xf

G

ic

-d
-b

Ju
eo

10

ot
Pr

M
eP
h

t
rio
ha
C

5

G

ec
Xf

ic

-d

Ju

-b
10

eo

ot
Pr

M
eP
h

t
rio
ha
C

5

G

ec
Xf

ic

-d

Ju

-b
10

eo

ot
Pr

M
eP
h

rio
ha
C

e

0

G

0

-d

0

ic

20

0

Ju

20

-b

20

eo

40

20

10

40

ot

40

Pr

60

40

M
eP
h

80

60

Serum Free Media
Complete Media

t

80

60

e

80

60

PU
LS
in

80

t

100

e

100

PU
LS
in

100

t

100

e

120

t

120

PU
LS
in

HeLa
120

PU
LS
in

Viability (%)

Jurkats
120

Figure 0.2. Viability as determined by 7-AAD of the cells treated with the proteincarrier complexes in both serum free (blue) and complete media (red). Samples were
normalized against the untreated control and the mean ± SEM is shown for three
separate experiments.
Most notably, the PTDM used here could deliver into a high percentage of all cell
types in both serum free and serum containing conditions and had a large shift in MFI,
indicating that most of the cells were receiving a large portion of protein. As seen with the
other transfection reagents, the presence of serum slightly hampers the delivery of GFP. A
decrease in viability was seen in Jurkats in the case of delivery with the PTDM in serum
free conditions, but the other cell types seemed unaffected. In all cases the PTDM in
complete media out performs the optimized conditions of the other delivery reagents in all
cell types (serum free conditions).
4.4. Conclusion
While many products are being developed for protein delivery, all the commercially
available options within the class of amphiphilic polymers require optimization,
performing only in serum free conditions, and do not deliver a large payload into the cells
of interest. Here, we demonstrate the use of a polymeric peptide mimic (PTDM) that is
capable of non-covalent protein delivery of GFP into a variety of cell types in complete
media, outperforming its commercially available counterparts within the same class of
amphiphilic polymers. In all cell types, the PTDM was able to deliver significantly higher
amounts of protein into over 80% of cells both in serum free and serum containing
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conditions. Future work on understanding how amphiphilic polymers interact with their
cargo protein, as well as protein in the media will enhance development of protein delivery
into cells.
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CHAPTER 5
PROTEIN TRANSDUCTION DOMAIN MIMICS FACILITATE RAPID
ANTIGEN DELIVERY INTO MONOCYTES
5.1. Introduction
Vaccines are currently one of the most effective means of preventing diseases and
are actively being sought after to train the immune system against innately harder to treat
diseases such as cancer and HIV as more of a therapeutic approach.233 For protein based
vaccines, delivering the antigen into the cytosol has considerable challenges due to the
impermeability of the cell membrane.234 A diversity of approaches has been explored for
delivering antigens to optimally stimulate a T cells and mount an adaptive immune
response.235–237
A sustained T cell response is driven by activation by an antigen presenting cell
(APC), the bridge between the innate and adaptive immune system. Professional APCs,
such as macrophages, B cells, and dendritic cells (DCs), promote the activation and
proliferation of T cells against their major histocompatibility complexes (MHCs)
displaying a specific antigen.238 When a circulating activated CD8+ T cell recognizes
material presented in an MHC class I that is foreign, it induces apoptosis in the host cell.
The distinction between the T cells is important because CD4+ T cells, also known as
helper T cells, promote an inflammatory environment that encourages the proliferation of
B cells and subsequent antibody production against the foreign material. CD8+ T cells,
also known as cytotoxic T lymphocytes (CTLs), function to destroy infected or deformed
cells within the body.
Two types of MHCs exist; class I, located on all cell types, interacts with CD8+ T
cells, while class II, only present on professional antigen presenting cells, is associated
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with CD4+ T cells. The role of the MHC is to present both foreign and endogenous peptides
to the immune system and, in the case of APCs, to train T cells against foreign material. In
APCs, antigen presentation happens via two processes; material that is taken up through
endosomes is degraded by proteases and fuses with endosomes produced by the ER that
contain MHC class II, while exogenous material in the cytosol is degraded by proteasomes
and shuttled to the ER where it is loaded on MHC class I.238 In either case, once the peptide
is loaded onto the MHC, the complex is then transported to the cell surface, where it can
be accessed by T cell receptors. A schematic of both processes is presented in Figure 0.1.

Class II MHC
Pathway
APC
TCR

CD4
CD 4+
T Cell

Class I MHC
Pathway
CD8
TCR

Cytokines

CD 8+
T Cell

Figure 0.1. Processing and presentation of exogenous proteins by antigen presenting
cells. If the protein is present in the cytosol of the APC, it is processed by a proteasome
and trafficked to the ER where it is loaded through the MHC class I pathway to prime
CD8+ T cells. Endosomal uptake of antigen is processed through the class II MHC
pathway where the protein is degraded within the endosome, which fuses with vesicles
with the MHC class II and presented to prime CD4+ T cells. Along with presentation
secondary co-stimulation from the CD4 or CD8 with CD80 and CD86 along with
cytokine production is required for activation of both types of T cells.
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Besides antigen recognition by the T cell receptor, T cells require co-stimulation
and cytokine stimulation to be activated and begin proliferating.239 APCs upregulate the
expression of costimulatory molecules, such as CD40, CD80, and CD86, and the secretion
of cytokines, like INF-g, IL-1b, TNF-a, and IL-12p70, when they are triggered by danger
signals such as agonist like toll-like receptors (TLRs).240
Almost all vaccines are based on exogenous antigens being endocytosed,
processed, and presented through the major histocompatibility complex (MHC) class II.
The antigen loaded MHC II then interacts, along with co-stimulatory molecules, with naïve
CD4+ T cells which then become activated and begin to divide, promoting an immune
response against the specific antigen.
Activation of CD8+ T cells is slightly more complicated because it requires the
antigen presenting cell to have the foreign material available in the cytosol. While possible,
this event is rare due to the integrity of the cell membrane and the low number of APCs
compared with other cell types in the case of viral infection. If the foreign material is
present in the cytosol, the APC displays the antigen on the MHC I and, along with
costimulatory molecules (CD86, CD80, and CD40), stimulates CD8+ T cells specific to
that antigen to divide and become activated.
In addition to the two classical loading mechanisms, some APCs are able to shuttle
antigen from endosomes (normally destined for loading on MHC class II molecules) into
the MHC class I pathway.241 This process is known as cross-presentation and it facilitates
a CTL response, but is only efficiently performed by dendritic cells (DCs). Along with
their ubiquitous presence throughout the body and their ability to efficiently activate naïve
T cells, DCs are a key target for therapeutic vaccines. In an effort to increase DC numbers
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and immune activation, several targeting strategies have been employed to increase uptake
in monocytes, a DC precursor.242–246 Since monocytes require differentiation into DCs, one
strategy that has been explored is the co-formulation of the antigen with endosomal TLR
agonists.244,247
Designing an effective MHC I vaccine is the grail of immunotherapy because it
would allow for the training and expansion of CTLs against a very specific epitope. Recent
advances in understanding antigen presentation by the innate immune cells and their
interaction with the adaptive immune system have facilitated a rational approach for design
and development of vaccine delivery systems. The key elements of an effective vaccine
are the antigen, or the motif to mount an immune response against, an agonist to stimulate
the innate immune system, and a delivery system to facilitate the uptake of the cargos into
the cytosol of APCs for presentation on MHC class I.139
Nanocarriers are well suited for vaccines because they provide encapsulation of the
antigen and agonist, as well as allow for delivery into the cytosol of APCs for priming of
CTLs. Recently, there has been a substantial increase in publications around immunization
based on synthetic carriers, advancing our understanding of important design criteria to
elicit a robust immune response with minimal toxicity.139 Many of these nanocarriers are
able exhibit a strong immune response both in vitro and in vivo, demonstrating their ability
to prime CTLs against a specific antigen.89,90,234,248,249
In addition to a variety of lipid and synthetic carriers, cell penetrating peptides
(CPPs) have been studied for intracellular delivery in vaccine delivery systems.233,250
Previous reports use either chemical conjugation or a fusion construct with different types
of antigen cargos, including protein, peptides, DNA, and siRNA.158,251,252 Apart from
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facilitating intracellular delivery, several examples of CPPs have been reported to prime
antigen-specific CTLs.252–258 CPPs are attractive because they offer an all-inclusive
delivery platform that has shown enhanced immune stimulation, though there are still many
barriers to overcome in this field.233
Although straightforward, CPPs often require conjugation to their cargo.
Previously, we have shown non-covalent delivery of functional cargos into the cytosol and
nucleus of T cells using synthetic CPPs, also termed protein transduction domain mimics
(PTDMs).134,259 In addition to T cells, we have shown uptake into a variety of other cell
types (unpublished), suggesting that the PTDM might provide a facile solution to
delivering antigen into the cytosol of APCs. Herein, we describe the optimization of
delivering the model antigen SIINFEKL into monocytes in whole blood, as well as
immature dendritic cells in vitro for presentation on the MHC class I using an amphiphilic
block copolymer. Additionally, the differentiation of the monocytes and production of
inflammatory cytokines was explored when the antigen was delivered with the endosomal
TLR9 agonist CpG. Understanding the efficacy of these PTD mimics provides an important
foundation for future applications of PTD technology in the field of peptide-based vaccines
towards intracellular pathogens and immunomodulation of disease.
5.2. Materials and Methods
5.2.1. PTDM Synthesis and Characterization
Monomers and polymers were synthesized according to previously established
procedures as reported in 2.2.3.229,260 Briefly, to create the monomer, the exo Diels-Alder
adduct of maleic anhydride and furan was ring-opened with the desired alcohol to introduce
the first substituent. A second alcohol was then added using EDC coupling. The desired
polymers were obtained by ring-opening metathesis polymerization using Grubb’s third
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generation catalyst in dichloromethane and end terminated with either ethyl vinyl ether or
an activated ester, which was then reacted with FITC. After polymerization, the Boc groups
protecting the guanidinium groups were removed with a 1:1 solution of trifluoroacetic acid
and dichloromethane. The final products were purified by dialysis against RO water and
recovered by lyophilization.
5.2.2. Cell Preparation
5.2.2.1.

Whole Blood

Whole human blood was obtained from healthy volunteers under signed consent in
BD Vacutainers containing hirudin. In all cases, blood was used within 10 minutes of the
tapping from the donor. The blood was distributed into Eppendorf tubes containing
preassembled polymer preparations in RPMI 1640 with no supplements and incubated up
to 1 hour at 37˚C on rotation (60 RPM). In general, 400 µL of blood was combined with
100 µL of polymer complex prepared in RPMI 1640 for a final volume of 500 µL.
In the case of plasma free whole blood delivery, whole blood was centrifuged at
200 g immediately upon receipt, plasma was removed, and cells were washed with RPMI
1640 three times before suspension to the original volume with RPMI 1640. The washed
blood was then allocated to the polymer preparations and incubated on rotation (60 RPM)
for 1 hour at 37˚C.
5.2.2.2.

Cell Lines

Jurkat T cells (clone E6-1, ATCC TIB-152) and THP-1 cells (ATCC TIB-202),
were grown in RPMI 1640 supplemented with 10% (v/v) FBS, L-glutamine, Non Essential
Amino Acids (NEAA), Na-pyruvate, HEPES, 100 U/mL penicillin, and 100 U/mL
streptomycin at 37˚C, 5% CO2 and were passaged 24 hours before treatment. Polymers
were mixed with cargo and allowed to complex for 30 minutes. Jurkats were harvested and
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suspended in fresh complete media and placed into a 12 well plate at 4X105 cells/mL.
Polymer-cargo complexes were applied drop-wise to each well. Cells were treated for 4
hours, then washed 3 times with 20 U/mL heparin in PBS before being suspended in 0.2%
BSA in PBS FACS buffer and stained with 7-AAD for analysis by flow cytometry.
To establish immature dendritic cells, previously established protocols were
used.261 Briefly, THP-1s were incubated with 100 ng/mL IL-4 and 100 ng/mL GM-CSF
for 5 days, with the media and cytokines being replaced every 2 days. Differentiation was
confirmed by increased expression in CD11c and HLA-DR as well as a morphological
change.
5.2.2.3.

Bone Marrow Derived Dendritic Cells

Immature dendritic cells were differentiated from murine bone marrow according
to established protocols.262 Discarded legs from C57BL/6 mice were graciously donated
by the Pobezinsky lab. Bones were cleaned with ethanol and cells were harvested using a
28-gauge syringe. RBCs were lysed using BioLegend® lysis buffer and cells were plated
at a density of 2X105 cells/mL in complete RPMI (listed under cell lines) with the addition
of 20 ng/mL recombinant mouse GM-CSF. Cells were cultured for 6 days with the addition
of 10 mL fresh media and cytokines on day 3. Non-adherent and loosely adherent cells
were harvested on day 6 and cells were pelleted, counted, and plated at a density of 2X106
cells/mL.
5.2.3. Flow Cytometry
After incubation, cells were pelleted at 200 g for 5 minutes and the supernatant was
removed. Red blood cells were lysed in using BD Pharm lysis buffer and subsequently
washed with 1% FBS in PBS twice before staining with antibodies. Unspecific binding
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was blocked for 10 minutes using human or mouse IgG respectively. Antibody surface
staining was performed using antibodies for Human CD14-APC, CD40-PE, CD80-AF488,
CD86-BV711, CD209-APC, HLA-DR-APC-Cy7, or Mouse CD11c-AF488, CD86AF647, HLA-DR, H-2Kb-PE as indicated by manufacturer (BD® or BioLegend®).
Briefly, cells were transferred to a 96 well plate where the respective antibodies
were added accordingly. Samples were incubated for 30 minutes on ice after which samples
were washed 3 times with 1% FBS in PBS before analysis by flow cytometry.
Whole blood samples were collected on a BD® Accuri C6™ flow cytometer with
two lasers (488 and 640nm) with three channels on the blue laser (533/30, 585/40, and 670
LP) and one channel on the red laser (675/25). For whole blood experiments, 100,000
single events were collected for each sample using a minimum FSC-H cutoff of 1,200,000.
THP-1 monocytes, immature dendritic cells, and bone marrow derived dendritic
cells were analyzed using a BD LSR Fortessa 20X flow cytometer with five lasers and 18
channels. For both cell lines, 10,000 single events were collected for each sample, while
for the bone marrow derived cells, a minimum of 50,000 single cell events were collected.
Only cells negative for 7-AAD were assessed for either uptake or presentation of markers.
Multi-color flow cytometric analysis spectral overlap was corrected by appropriate
compensation and analyzed using FlowJo™ 10.2 by Tree Star®.
5.2.4. Cytokine Profiling
After one hour of incubation with treatment as reported under cell preparation and
culture, cells were pelleted at 400 g for 2 minutes and supernatant was removed. Cells were
washed 3 times with RPMI supplemented with 100 U/mL pen/strep, and plated into a 96
well round bottom plate where they were incubated at 37˚C and 5% CO2 for 24 hours. After
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incubation, cells were pelleted at 5000g and supernatant was transferred to a fresh 96 well
plate and frozen at -80˚C until testing. Measurements of IL-6 were performed immediately
after thawing frozen supernatant using ELISA, R&D Systems. Cytokine production was
detected using the inflammatory cytometric bead array Legendplex™ from BioLegend®
which included IL-1b, IFN-a, IFN-g, TNF-a, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL17A, IL-18, IL-23, and IL-33.
5.2.5. Statistical Analysis
All flow cytometry experiments were repeated in at least biological triplicate. Data
sets were expressed as means ± SEM Statistical significance of differences was determined
by one or two way ANOVA followed by a Bonferroni post hoc test. Differences were
considered statistically significant for p<0.05. Statistical analysis was performed using
Prism™ 5.0a by Graphpad® Software.
5.3. Results and Discussion
5.3.1. MePh10-b-dG5-FITC Treatment of Whole Blood
To understand the interaction of the PTDM with cells in whole blood, FITC labeled
MePh10-b-dG5 (Figure 0.2A) was added to freshly collected human whole blood for 1 hour
at a final concentration of 2.8 µM. After lysis of red blood cells (RBCs) and staining with
anti-CD14 and anti-CD15, polymer showed low association with granulocytes (CD15+)
and lymphocytes (morphological gate) as seen in Figure 0.2C, while the MFI and uptake
in monocytes (CD14+) was statistically higher than the blank and the other two cell
populations. Viability, determined by staining with 7-AAD, was not statistically different
from the blank with 95.8 ± 1.6 % live cells.
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Figure 0.2. Delivery of 2.8 µM FITC labeled polymer (A) into whole blood for 1 hour.
Cells were gated morphologically (B) and monocytes were confirmed with CD14
staining, while granulocytes were confirmed with CD15 staining within the respective
morphological gate. Uptake within each of the morphological gates was determined
by a shift in FITC intensity from the blank (C). The mean±SEM of the median
fluorescence intensity (MFI) on the top and percent positive cells on the bottom of 4
separate donors is shown (D).
Specific uptake by the monocyte population is interesting but slightly unsuprising
due to their phagocytotic nature. Since we have previously shown delivery into a variety
of cell types, the logical next step was to deliver a cargo complexed with the polymer.
SIINFEKL peptide, the MHC class I specific sequence of ovalbumin (OVA) was chosen
as a model antigen.
5.3.2. Optimization of Delivery into Jurkat T Cells
In order to determine the most effective concentration of peptide and the subsequent
ratio of peptide to polymer (MePh10-b-dG5), a survey of peptide concentrations (0.1, 0.5,
1, and 5 µM) crossed with protein to polymer ratios (1:5, 1:10, 1:15, and 1:20) was
investigated in Jurkats. In this case, SIINFEKL was fluorescently labeled with FAM to
showcase ability of cargo delivery. Peptide-polymer complexes were allowed to form for
30 minutes prior to addition to the cells in complete RPMI. Cells were treated for 4 hours,
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after which they were washed three times with heparin to remove excess peptide adhered
to the outside of the cell. Uptake and viability (7-AAD staining) was assessed using flow
cytometry and is shown in Figure 0.3. The trend between peptide to polymer ratios was
consistent across all peptide concentrations, with a ratio of 1:10 performing similarly to
1:20 indicating that higher ratios of polymer would not necessarily enhance delivery.
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Figure 0.3. A concentration survey for the delivery of SIINFEKL into Jurkat T cells
at varying ratios of peptide to polymer. Cells were treated with the complexes for 4
hours, washed three times with heparin, and analyzed by flow cytometry for their
ability to deliver SIINFEKL. Viability (left) was determined using 7-AAD, MFI
(middle) indicates the amount of peptide delivered to the cells, and % positive cells
(right) indicates the population of cells that were delivered into. Experiments were
repeated in triplicate and the mean and SEM are displayed.
5.3.3. Time Survey of Peptide Delivery into Whole Blood
The specificity of uptake of the polymer-antigen complex by monocytes was tested
in whole blood. 1 µM FAM labeled SIIFNEKL was delivered into whole blood using
MePh10-b-dG5 at a ratio of 1:10, for 15, 30, 45, or 60 minutes to investigate the kinetics of
uptake. MFI and uptake were not statistically different regardless of the incubation time.
Additionally, complex uptake was compared with free SIINFEKL-FAM allowed to
incubate with whole blood for 60 minutes. High association with the monocytes is seen
within the first 15 minutes (Figure 0.4) compared with lymphocytes and granulocytes,
consistent with the previous observations. The free peptide is not readily taken up in large
amounts by any of the white blood cells.
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Figure 0.4. Delivery of fluorescently labeled SIINFEKL complexed with PTDM at a
ratio of 1:10 into whole blood for 15, 30, 45, and 60 minutes. Whole blood was also
treated with soluble SIINFEKL for 60 minutes as a comparison. Cell types were gated
on morphologically then with CD14 and CD15 to determine true monocytes and
macrophages, respectively. The mean and SEM of 4 separate donors is displayed for
the MFI (left) and % positive (MFI) cells within the established gates.
Rapid specific uptake of the fluorescently labeled antigen in monocytes showcases
the ability of the PTDM to significantly enhance uptake of the model cargo. The relatively
low association and uptake seen with the free peptide suggests that some property of the
polymer enhances association and uptake with monocytes. Since the PTDM has been
shown to deliver into multiple cell types, increased concentrations were investigated for
induced uptake in the granulocyte and lymphocyte populations.
5.3.4. Concentration Survey of Peptide Delivery into Whole Blood
FAM labeled SIINFEKL was delivered into whole blood using MePh10-b-dG5 at a
ratio of 1:10 at increasing concentrations of peptide (0.25, 0.5, 1, and 2 µM). The MFI and
% positive cells are shown in Figure 0.5A, suggesting that 1 µM of peptide was optimal
because almost 100% of the cells show uptake and the MFI is significantly distinguishable
from the untreated sample. Increasing the concentration to 2 µM appears to yield a higher
MFI, but also requires more polymer. High uptake was exhibited almost exclusively in the
monocytes labeled with CD14 and not significantly in the lymphocytes and granulocytes,
consistent with the previous observations.
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Figure 0.5. (A)Delivery of fluorescently labeled SIINFEKL complexed with PTDM at
a ratio of 1:10 into whole blood at peptide concentrations of 0.25, 0.5, 1, and 2 µM of
peptide. Cell types were gated on morphologically then with CD14 and CD15 to
determine true monocytes and macrophages, respectively. (B) IL-6 production was
determined for unlabeled SIINFEKL delivered under the same conditions 24 hours
after treatment in comparison to the positive control Resiquimod, a TLR7 agonist.
The mean± SEM of 4 separate donors is displayed.
Even at high concentrations, uptake is promoted in only the monocyte population,
confirming that the polymer promotes specific interaction with these phagocytic cells.
Although uptake is promoted, monocytes themselves do not serve a specific function in
terms of promoting a specific immune response. Monocytes can differentiate into two types
professional antigen presenting cells, macrophages and dendritic cells, upon stimulation
and activation.238 Usually, the differentiation into dendritic cells can be marked by a change
in cell specific surface marker expression such as upregulation of MHC class I and DCsign (CD209) as well as in inflammatory cytokine production.261,263
To further investigate the ability of the polymer-peptide complexes to cause an
inflammatory cytokine environment, whole blood was treated with the same conditions as
in the concentration survey (0.25, 0.5, 1, and 2 µM peptide at a 1:10 peptide to polymer
ratio) and the production of IL-6 was probed 24 hours after the treatment (Figure 0.5B).
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The whole blood was added to the polymer complexes for 1 hour on rotation, after which
the plasma was removed and the cells were washed three times with non-supplemented
RPMI. The cells were incubated at 37˚C for an additional 24 hours and the supernatant was
collected to perform an IL-6 ELISA. No significant IL-6 production detected with any of
the treatments, except the positive control Resiquimod, a TLR7 agonist. The results
indicate the polymers alone and in complex with SIINFEKL do not produce proinflammatory signals in blood, even at high concentrations. Since the complexes show high
uptake but are not inflammatory, they most likely do not cause the monocytes to
differentiate. The differentiation and activation of the monocytes in whole blood can be
induced by delivering an agonist in addition to the antigen.
5.3.5. SIINFEKL Delivery with Amphiphilic Peptides
Since high uptake in monocytes was demonstrated using MePh10-b-dG5, similar
peptides were tested to compare their ability to non-covalently associate SIINFEKL and
facilitate uptake in whole blood. Two peptides were chosen, R9 and Pep-1, for their
cationic nature and previously shown ability to translocate cells to deliver biomolecular
cargo.35,119 As before, the peptides were complexed for 30 minutes in the presence of
SIINFEKL. Since delivery in the presence of protein inhibits the ability of many carriers
to deliver into cells, the plasma was removed from the blood by washing with RPMI three
times and suspending the cells back to the original collected volume. The plasma free blood
was then added to the complexes and put on rotation for 1 hour at 37˚C after which the
RBCs were lysed and cells were stained with anti-CD14.
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Figure 0.6. Delivery of fluorescently labeled SIINFEKL into whole blood using the
well known cell penetrating peptides pep-1 and R9 in comparison with MePh10-b-dG5
after 1 hour incubation. Cell types were gated on morphologically then with CD14
and CD15 to determine true monocytes and macrophages, respectively. The mean
and SEM of 6 separate donors is displayed for the MFI (left) and % positive (MFI)
cells within the established gates.
Analysis by flow cytometry, shown in Figure 0.6, indicated negligible delivery
when the SIINFEKL was introduced by itself or in the presence of the tested peptides. In
contrast, the MePh10-b-dG5 facilitated uptake in the monocytes, clarifying that plasma
proteins are not directly responsible for the uptake of the polymer-antigen complex in terms
of aggregation or opsonization.
5.3.6. Optimization of CpG and OVA Protein Ratio to Polymer
To introduce a controlled cytokine response, CpG, a TLR9 nucleotide agonist was
chosen for co-delivery with the chosen agonist. Since the polymers studied here have never
been tested for co-delivery, optimization was required to determine the optimal ratio of
polymer to CpG and the protein OVA, as well as any requirements about complex
formation. In this case, the whole protein was chosen over the peptide antigen due to the
compatibility of fluorophores that were readily available for each of the cargos.
Additionally, a second polymer, dPh10-b-dG5, was added to briefly determine if polymer
architecture would affect association and uptake of the two different cargos.
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The delivery of CpG-FITC and OVA-AF647 were optimized separately in Jurkats
through determining the optimal N/P ratio for 100 nM CpG and protein/polymer ratio for
50 nM OVA. Cargos were complexed with two polymers (MePh10-b-dG5 and dPh10-bdG5) at increasing ratios for 30 minutes in PBS. N/P ratios of 1:1, 2:1, 4:1 and 8:1 (Figure
0.7A and B) and protein-polymer ratios of 1:5, 1:10, 1:20, and 1:40 (Figure 0.7C and D)
were assessed for CpG and OVA, respectively. Complexes were added drop-wise to
Jurkats and incubated at 37˚C for 4 hours after which they were washed with heparin to
remove any residual cargo stuck to the outside of the membrane and uptake was assessed
by flow cytometry. CpG-FITC delivery peaked at a ratio of 4:1 for both polymers, while
OVA delivery was best at a ratio of 1:40 for the MePh10-b-dG5 compared with 1:20 being
sufficient for the dPh10-b-dG5.

109

B.

100

2500
2000

80

MFI of CpG

% CpG Positive

A.

60
40

1000
500

20

0

0
MePh10 -b-dG 5

MePh10 -b-dG 5

dPh10 -b-dG 5

C.

dPh10 -b-dG 5

D.
140000
120000
100000
80000
60000

100
80

MFI of OVA

% OVA Positive

Blank
1:1
2:1
4:1
8:1

1500

60
40
20

15000
10000
5000
0

0
MePh10 -b-dG 5

MePh10 -b-dG 5

dPh10 -b-dG 5

dPh10 -b-dG 5

Blank
1:5
1:10
1:20
1:40

Figure 0.7. Optimization for delivery of CpG-FITC and Ovalbumin (OVA-AF647) in
Jurkat T cells to determine the optimal ratio of cargo to polymer. Two polymers were
assessed for their ability to deliver both cargos. Polymers were complexed with 100
nM CpG at N:P ratios of 1:1, 2:1, 4:1, and 8:1 for 30 minutes and then applied to cells
in complete media for 4 hours. The percentage of cells positive for CpG (A) and MFI
(B) were determined by flow cytometry. 50 nM OVA was complexed with the
polymers at ratios of 1:5, 1:10, 1:20, and 1:40 prior to 4 hours of delivery. Similarly,
percent positive (C) and the MFI (D) were assessed via flow cytometry. The mean and
SEM are displayed for three independent experiments.
The ability of the polymers to deliver the CpG and OVA into the same cell was
tested for the necessity to complex the cargos with the polymers separately (postmix) or
together with the polymer at the same time (premix). In the case of postmix, the cargos
were mixed with either MePh10-b-dG5 or dPh10-b-dG5 and allowed to complex before
simultaneous addition of the antigen complex and agonist complex to the cells, while in
the premix version, all three substituents were added and allowed to complex together
before addition to the cells. The fluorescence intensity of both cargos was assessed by flow
cytometry after 4 hours incubation and subsequent heparin washing (Figure 0.8).
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Figure 0.8. Optimization of co-delivery of 100 nM CpG-FITC and 50 µM OVA-AF647
into Jurkat T cells. MePh10-b-dG5 or dPh10-b-dG5 was complexed with CpG and OVA
either individually (postmix) or all together (premix) for 30 minutes before treatment
of cells in complete media. The MFI for CpG (A) and OVA (C) were assessed
individually on the population as a whole. The percentage of cells positive for both
cargo types (B) was assessed along with Viability (D) using 7-AAD after 4 hours by
flow cytometry. The mean and SEM are shown for 3 independent experiments.
For the single polymer samples (MePh+CpG+OVA and dPh+CpG+OVA), no
statistical difference was seen between the set that was mixed individually (PTDM with
OVA separate from PTDM with CpG) and those that were mixed together (PTDM with
OVA and CPG). Additionally, both polymers appeared to deliver with the same efficacy.
When both polymers were used together to complex cargo, the premix strategy was far
superior. Consequently, premixing everything together was adopted and only MePh10-bdG5 was continued with for all subsequent co-delivery experiments.
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5.3.7. Co-Delivery of CpG and OVA in Whole Blood
After optimization, the polymer-antigen-agonist complex was delivered into whole
blood to see if the addition of the agonist effected the association with monocytes and if
the complex promoted differentiation or activation. CpG and OVA were premixed with the
polymers at the previously determined ratios of N/P = 4:1 for the CpG and 1:20 or 1:40 for
the respective polymers with increasing concentrations of CpG. Whole blood was treated
with the various complexes for 60 minutes to investigate uptake. Based on MFI, Figure
0.9, the polymers cause significantly higher uptake in the morphological granulocytes and
monocytes gates at the higher concentrations. It was apparent with the loss of cells within
the typical monocyte morphological gate that the assay was inconclusive. The cells positive
for both OVA and CpG lie within the lower side of the granulocyte population. Further
evidence to support the idea of monocyte differentiation into macrophages, and the
subsequent shift up in side scatter is required. To follow up, delivery into a single culture
of monocytes was investigated.
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Figure 0.9. Co-delivery of CpG-FITC and OVA-AF647 complexed with MePh10-bdG5 into whole blood. Increasing concentrations of CpG were used (50, 100, and 200
nM) along with 50 nM OVA protein. Uptake into the morphological granulocyte,
lymphocyte, and monocyte gates are shown as a function of CpG MFI (top), OVA
MFI (middle), and percentage of cells positive for both cargos (bottom).
To quickly check for upregulation of differentiation marker DC-sign, the complex
was compared with treatment of whole blood with IL-4 and GM-CSF, cytokines that can
be used to induce differentiation into dendritic cells. After 1 hour of treatment, followed
by washing and a 24 hour incubation, the cells treated with the polymer-antigen-agonist
complex showed a slight increase in upregulation of DC-sign, as seen in Figure 0.10, but
the increase was not substantial in relation to the cytokine treated cells. It is possible that
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at a longer time point higher upregulation of this marker would occur. Alternatively, the
amount of CpG added might be too low to cause significant upregulation of DC-sign.

Figure 0.10. Co-delivery of SIINFEKL and CpG with MePh10-b-dG5 compared with
cytokine treatment to differentiate monocytes into dendritic cells. Whole blood was
treated for 1 hour, then washed and incubated for an additional 24 hours to look at
the upregulation of DC-sign (CD209) within the monocyte (CD14) population. The
PBS negative control (left) and cytokine positive control (middle) compared with the
polymer-antigen-agonist complexes.
5.3.8. Delivery into THP-1 Monocytes
A multi-analyte inflammatory cytokine panel was used to understand the immune
response for the addition of CpG into the complexes. Supernatants from whole blood at 24
hours after a 60 minute treatment with the polymer-SIINFEKL-CpG complexes were tested
using a standardized inflammation panel including IL-1b, IFN-a, IFN-g, TNF-a, MCP-1,
IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33. A statistical summary of
cytokine production is summarized in Table 0.1. When CpG was delivered by itself, it
caused an increase in IL-1b, IFN-a IFN-g, TNF-a, IL-6, MCP-1, and IL-12p70, which are
all indicative of a pro-inflammatory response directed by the differentiation and activation
of professional antigen presenting cells. In general, cytokine response with the addition of
SIINFEKL did not change this profile suggesting that the two cargos can be delivered
together to perform their individual functions. Additionally, the production of IL-12p70 is
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especially interesting because it indicates the active heterodimer is being produced by
APCs to stimulate T cells. In combination with INF-g and TNF-a, IL-12p70 enhances the
cytotoxic activity of CTLs suggesting that the delivery of CpG and SIINFEKL with the
PTDM may facilitate an enhanced immune response.
Table 0.1. Inflammatory cytokine panel for the co-delivery of SIINFEKL and CpG
using MePh10-b-dG5 into whole blood. Supernatant was collected 24 hours after
treatment and analyzed using a cytometric bead array. Statistical difference was
determined from the untreated sample from 3 independent donors (*p<0.05,
**p<0.005, ***p<0.0005)

5.3.8.1.

Cytokine Response to Co-Delivery of SIINFEKL and CpG

FAM labeled SIINFEKL or OVA labeled with FITC were delivered respectively
using MePh10-b-dG5 into THP-1s, a human monocyte cell line. 1 µM of each cargo was
complexed respectively with the polymer at a 1:10 protein/peptide to polymer ratio for 30
minutes before application to cells in complete media. The lowered ratio used in this
experiment was an attempt to lower the amount of polymer required and therefore mitigate
cytotoxicity. Cells were treated for 4 hours, then washed 3 times with 20 U/mL heparin
prior to analysis by flow cytometry. The MePh10-b-dG5 facilitated delivery of both cargos
into the THP-1 monocytes, shown in Figure 0.1A and B, confirming its ability to deliver
into this cell type. Viability, determined by 7-AAD staining, remained similar to untreated
cells above 95% in relation to the untreated blank.
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Figure 0.11. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) into THP-1 cells
using MePh10-b-dG5. Cells were treated for 4 hours, then washed 3 times with heparin
(20 U/mL) and assessed for uptake of the cargos by flow cytometry. Upregulation of
activation surface markers (C) on THP-1s 24 hours after delivery of polymer-antigenagonist complexes. Cells were treated for 4 hours, then washed one time with media
and allowed to incubate for 20 more hours. LPS was used as a positive control. Cells
were stained with antibodies for DC-sign (CD209), HLA-DR (MHC II), CD86, CD80,
and CD40. The mean ± SEM are shown from 3 independent experiments.
To investigate the differentiation and activation of the monocytes by a polymerantigen-agonist complex, the 10 µM MePh10-b-dG5 was complexed with 1 µM unlabeled
SIINFEKL or OVA along with 1 µM CpG, a TLR9 agonist, for 30 minutes and cells were
treated for four hours. The cells were centrifuged and washed one time with PBS before
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being suspended in complete media for an additional 20 hours, after which the supernatant
was collected for ELISA and the cells were stained with antibodies for CD11c (a DC
marker), CD40, CD80, CD86, and MHC class II (HLA-DR). Minor upregulation of the
CD40, CD80, and CD86 could be seen in samples treated with the polymer-antigen-agonist
complex (Figure 0.11C).
Although a multi-analyte cytometric bead array was used to determine cytokine
production during the 20 hour incubation after treatment, no statistical increase was seen
in any of the analytes, not even when treated with LPS, the positive control. These results
may be due to too low cytokine concentration in all of the samples, requiring the
experiment to be done in a higher density of cells with a lower volume, over a variety of
time points. It is also possible that the monocytes were not stimulated enough by the
concentrations of polymer-antigen-agonist and that higher concentrations of the complexes
would lead to more definitive results.
5.3.9. Delivery into Immature Dendritic Cells
Delivery into immature dendritic cells (iDCs) was also investigated in partially
differentiated antigen presenting cells. iDCs were stimulated for 6 days to cause
upregulation of MHC class II (HLA-DR) and DC-sign, indicating their ability to be primed
for T cell stimulation. Similar to the THP-1s, 1 µM fluorescently labeled SIINFEKL or
OVA complexed with MePh10-b-dG5 at a ratio of 1:10 were delivered into the iDCs
derived from THP-1s (Figure 0.12A and B), showing significant uptake of the peptide
compared with the free soluble counterpart. More variation of OVA protein uptake was
seen than with the Thp1s, possibly due to inconsistent differentiation between the three
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trials. The high SIINFEKL uptake in these cells indicate that the PTDM facilitates the
delivery of antigen into iDCs.

Figure 0.12. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) using MePh10-bdG5 into immature dendritic cells derived from the THP-1 cell line. Cells were treated
for 4 hours, then washed 3 times with heparin (20 U/mL) and assessed for uptake of
the cargos by flow cytometry. The mean and SEM are shown as a result of 3
independent experiments. Upregulation of activation surface markers (C) on iDCs 24
hours after delivery of polymer-antigen-agonist complexes. Cells were treated for 4
hours, then washed one time with media and allowed to incubate for 20 more hours.
LPS was used as a positive control. Cells were stained with antibodies for DC-sign,
MHC II, CD86, CD80, and CD40.
Co-delivery of the antigen and agonist was performed to probe upregulation of costimulatory molecules, as well as production of inflammatory cytokines. Surface marker
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staining, Figure 0.12C, revealed a slight upregulation of CD80, CD86, and CD40 in the
samples that received the polymer-antigen-agonist complex. Although the upregulation
was not substantial, it is possible that higher concentrations of CpG or for longer are
required to produce significant upregulation of surface markers and production of
inflammatory cytokines.
5.3.10. Delivery into Bone Marrow Derive Dendritic Cells
Perhaps the most conventional and telling way to scrutinize whether the PTDMantigen-agonist complex will enhance vaccination through delivery of a specific peptide is
to probe immature dendritic cells that would subsequently be able to stimulate T cells. In
this case, complexes are delivered into mouse bone marrow derived dendritic cells
(BMDCs) that would internally process the antigen via the MHC class I and class II
pathways and present the antigen along with respective costimulatory molecules. Since we
have chosen a peptide that is specifically presented in MHC class I, we can probe for the
display, as well as the upregulation of CD86, a costimulatory molecule.
To test SIINFEKL delivery and presentation for T cell activation, bone marrow
derived dendritic cells were differentiated from C57BL/6 mouse bone marrow for 6 days
in the presence of 20 ng/mL mouse GM-CSF. After 6 days, cells were harvested and treated
with 1 µM fluorescently labeled SIINFEKL or OVA both free and in complex with
MePh10-b-dG5 ratio of 1:10 for 4 hours. Substantial uptake was seen in the presence of
polymers while significantly less uptake was seen for the free antigen in both cases (Figure
0.13A and B).
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Figure 0.13. Delivery of SIINFEKL-FAM (A) and OVA-AF647 (B) using MePh10-bdG5 into immature dendritic cells derived from C57BL/6 mouse bone marrow. Cells
were treated for 4 hours, then washed 3 times with heparin (20 U/mL) and assessed
for uptake of the cargos by flow cytometry. Upregulation of activation markers (C)
on BMDCs 24 hours after delivery of polymer-antigen-agonist complexes. Cells were
treated for 4 hours, then washed one time with media and allowed to incubate for 20
more hours. LPS was used as a positive control. Cells were stained with antibodies
for MHC II, CD11c, CD86, and H-2Kb (presentation of SIINFEKL in MHC class I).
The mean and SEM are shown for BMDCs derived from 3 mice.
In addition to delivery of fluorescently labeled cargo, both OVA and SIINFEKL
were delivered in combination with 1 µM CpG to investigate presentation of SIINFEKL
in the MHC class I along with upregulation of CD86 and the production of inflammatory
cytokines indicating the ability of these DCs to activate T cells. After differentiation, cells
were treated for 4 hours with the polymer-antigen-agonist complexes, after which cells
were washed 1 time with PBS and suspended in fresh media for 20 hours. To determine
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upregulation, cells were stained with antibodies for CD11c and MHC class II to indicate
DCs, as well as CD86, and H-2Kb and results are shown in Figure 0.13C.
Since SIINFEKL can be extracellularly loaded into the MHC class I by diffusion,238
some display was expected just by adding the soluble peptide to the cells. The presentation
of SIINFEKL on the MHC class I was observed to be significantly higher for samples
treated with polymer-SIINFEKL-CpG compared with just soluble SIINFEKL alone or
when the polymer is used to deliver only the peptide. The high level of the antigen in the
MHC class I confirms that the complexes deliver and facilitate presentation for T cell
stimulation. Unexpectedly, the costimulatory molecule CD86 was not significantly
upregulated in any of the polymer treated samples, though the time point or concentration
of chosen agonist may directly affect display of this marker.
Additionally, samples treated with polymer-OVA-CpG did not result in any display
of SIINFEKL on the MHC class I as determined by staining with the H-2Kb. Lack of
display for OVA treated samples may be due to slow and inconsistent processing of the
OVA protein intracellularly. Higher presentation may be observed at a different time point
or at higher concentrations of OVA. While delivering a complete protein is conceptually
interesting, the ability to deliver a specific sequence or set of sequences allows more control
over what the specific immune response will be against.
5.4. Conclusion
In summary, we have shown specific delivery of SIINFEKL into monocytes in
whole blood is a rapid process, happening in under 15 minutes without concentration
dependence. The complex of the polymer with antigen does not appear to be immunogenic
even at increased concentrations lending the ability to tune the immunogenicity using the
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TLR9 agonist CpG. Additionally, the PTDM described here is superior to directing
monocyte uptake of the non-covalently complexed cargo when compared with amphiphilic
peptide counterparts.
When the SIINFEKL was delivered in combination with CpG in whole blood, a pro
dendritic cell cytokine environment was observed suggesting the differentiation of the
monocytes into professional APCs. The differentiation was not easily substantiated in the
mixed cell culture, so THP-1s were cultured with the polymer-antigen-agonist complexes
to investigate maturation of the monocytes. Although no inflammatory cytokines were
produced from the monocyte culture, there was a slight upregulation of CD40, CD80, and
CD86 suggesting that further time points as well as concentrations may elucidate whether
the monocytes differentiate. Similar results were seen in immature dendritic cells
differentiated from the THP-1s showing that uptake is possible in both cell types.
Delivery of both peptide and protein antigen into BMDCs showed high uptake.
High levels of presentation of the SIINFEKL in the MHC class I was observed in samples
treated with the polymer-SIINFEKL-CpG complexes indicating increased presentation.
Although no co-stimulatory molecules were detected, further investigation into the
concentration and timing of the complexes remains to be explored.
The enhanced display of SIINFEKL in MHC class I is a promising step toward
using PTDMs to stimulate a specific immune response using antigen presenting cells. This
study opens the door for further investigation of using amphiphilic polymers to promote
antigen and agonist delivery into antigen presenting cells for training and eliciting a
specified activation and response from CTLs. Future exploration is focused on the
expansion of T cells against the antigen and agonist treated BMDCs as well as
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understanding how concentration of the antigen and agonist are reflected in their ability to
promote a sustained T cell response.
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PERSPECTIVES AND FUTURE WORK
The exploration of how PTDM structure affects the internalization of cargo is just
at its beginning. Herein, we have motivated how small changes in length and
hydrophobicity can greatly influence the ability of protein delivery using non-covalent
interactions. Current work understanding how the polymers interact with their cargos is
underway and future exploration regarding how the structure of the polymer influences
self-assembly both in the presence and absence of serum would benefit the design of the
polymer system. The assembly properties may influence interaction with the cell
membrane, changing the ability of the polymers to permeate into the cytosol with their
cargo. To accomplish this, further experiments using light scattering should be combined
with ion exchange chromatography and cryo-TEM to fully understand self-assembly and
assembly with cargos.
In addition to fluorescence, proteins that have functional biological activity would
further bolster claims of cytosolic delivery. To date, Cre recombinase is the only enzymatic
protein that has been shown to have function in the cell.134 While it is encouraging that
delivered proteins retain their function, since we do not totally understand the polymer
protein interaction, it is hard to know if the PTDMs affect the function of the protein. To
explore this, a survey of enzymes should be delivered to correlate binding affinity with
protein function. Not only would a survey prove that the PTDMs are compatible with a
variety of proteins, it would also facilitate understanding of protein-polymer dynamics.
The CRISPR/Cas9 system is of particular interest because it would allow for gene
editing. Delivery of the ribonuclear protein in conjunction with the cRNA would enable a
simple, fast way to edit genomes of cells. Exploration of this protein cargo is already
underway with several research groups, suggesting that it can be achieved using the right
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protein carrier. Labeled versions of the protein and cRNA can be used to assess delivery
conditions, as well as what architecture polymer best delivers the cargo into cell. Enzymatic
activity can be easily tested using an T7E1 assay to determine gene knockout efficiency.
Alternatively, several designer cell lines exist that allow for knock out or knock in of
fluorescent genes. The ability to knock out a gene using the CRISPR/Cas9 system would
prove preserved enzyme functionality, as well as support the ability of the cargo to reach
the nucleus via delivery into the cytosol.
With a better understanding of how polymer structure can be tailored to different
types of cargo, PTDMs can be used in various capacities to probe molecular pathways in
immune cells through the delivery of proteins and antibodies. In terms of vaccines, we have
established the ability to deliver both an antigen and an agonist into both monocytes as well
as immature dendritic cells and see enhanced display of the antigen in the MHC class I at
a prolonged time point. The correct timing and concentrations of agonist to boost
costimulatory molecules and cytokines remains largely unexplored. Evaluation of the
effect of antigen and agonist concentrations on surface marker and cytokine expression
over a series of time points would provide insight into how much of these cargos are
required to facilitate an immune response. APCs derived from mouse bone marrow serve
as the best ex vivo example since comparable cell lines cannot express some of the classical
cytokines or markers.
Further optimization in terms of antigen presentation on APCs and T cell priming
would elucidate the ability of the PTDMs to help mount a specific T cell response against
the chosen antigen. Specifically, T cell proliferation against the delivered antigen, as well
as cytotoxicity of those trained T cells would provide evidence of enhanced vaccines. To
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achieve this, DCs differentiated from C57BL/6 bone marrow should be treated with
optimized antigen-agonist-polymer complexes as determined by production of high
cytokine levels of TNF-a and IFN-g along with upregulation of CD80 and CD86. After the
DCs are pulsed with the complex, CD8+ T cells isolated from OT1 mice with the same
C57BL/6 background and stained with CFSE should be co-cultured with the DCs to
investigate their ability to prime T cells. Expansion of this specific transgenic OT1 CD8+
T cell against the agonist OVA, will substantiate the ability of the polymers to deliver
functional antigen and prime an immune response.
Primed CD8+ T cells can be further tested for their cytotoxic functionality against
cells that display the delivered antigen. Several cell lines can be purchased that display the
OVA on their surface providing a model for how well the T cells are primed ex vivo. OT1
CD8+ T cells that have been expanded against the DCs treated with the antigen-agonistpolymer complexes could be co-cultured with a mouse cell line expressing OVA that has
either been stained or loaded with chromium. As the CD8+ T cells function as cytotoxic
killer cells against their target, chromium or dye will be released into the media and can be
measured either by radio isotopes or by flow cytometry respectively. High levels of cell
death will indicate that the T cells have been sufficiently primed against the OVA target
and are capable of providing an effective immune response against cell displaying the
target antigen.
Additionally, delivering other types of antigens and adjuvants by PTDMs into
APCs could be explored to ensure that they system translates to other cargos. Examples of
antigens that have readily available transgenic CD8+ T cell receptor models include gp100
and MUC1. Along with new antigens, several other adjuvants are being developed for
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clinical applications including TLR7 agonists and cytosolic danger signals that will
stimulate the STING pathway. New agonists, or a mixture of agonists may improve the
inflammatory response against the desired antigen and could easily be incorporated into
future work at any stage. Lastly, cytosolic signals to promote tolerance could also be
delivered into APCs to, causing otherwise active T cells to become senescent in the case
of autoimmunity.
The ultimate test of T cell priming would be to put the expanded T cells and DCs
back into an animal model with a tumor expressing the delivered antigen. If there were
stabilization or reduction in tumor size, it would confirm the robustness of the DC vaccine.
There are still many things to be optimized before these experiments could be achieved.
Further resources would be required in the form of collaboration to support animal studies.
Specifically, a group interested in the interface of oncology and immunity would provide
the support required to carry out such extensions of these PTDM delivery systems.
Overall, the PTDMs discussed here have demonstrated delivery of functional cargo
into a variety of cell types. Synthetically, the scaffold allows for tuning of molecular
architecture for probing structure activity relationships in terms of both membrane and
protein interactions. Additionally, functional protein delivery remains a largely uncharted
territory, rich with application regarding fundamental understanding of molecular
pathways. PTDMs provide many opportunities for future research at the materials
immunology nexus.
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